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ABSTRACT 
The Efficacy of Treatments for Childhood Depression : 
An Integrative Review 
by 
Kurt David Michael , Doctor of Philosophy 
Utah State University , 1999 
Major Professor : Dr. Susan L. Crowley 
Department: Psychology 
lll 
Prevalence estimates of child depression are substantial and morbidity leads to an 
increased risk of recurrence during adolescence and adulthood . Further , early-onset 
depression is associated with a number of negative outcomes including: poor physical 
health , social and interpersonal impairments , academic problems , substance abuse , future 
maladjustment , and suicidal behavior. In light of the prevalence , persistence, and 
negative outcomes associated with depression in children and adolescents , several 
treatments ranging from psychosocial to pharmacological interventions have been 
developed and evaluated. However, the overall efficacy of treatments remains equivocal 
because the majority of existing reviews of the child and adolescent depression treatment 
literature are narrative in nature, methodologically flawed , and/or present vague or 
conflicting conclusions. Although there are a number of good meta-analytic reviews that 
indicate that psychotherapy is effective with children and adolescents overall, 
comprehensive meta-analytic reviews focusing on the efficacy of psychological 
treatments specifically for depressed youth are nonexistent in the published literature. 
IV 
A comprehensive sample of studies on the psychosocial and pharmacological 
treatment of early-onset depression was located through an extensive literature search. 
Articles that met the inclusionary criteria were subsequently analyzed. The outcome data 
from 3 7 outcome studies were extracted and converted into effect sizes. Comparisons of 
main effects, potential interactions, and other specified variables were conducted. The 
overall findings of this meta-analysis indicate that several different psychosocial 
interventions for early-onset depression produce moderate to large treatment gains that 
are clinically meaningful for many afflicted youth. Further, it appears that psychosocial 
treatments are, in general, superior to pharmacological regimens in treating depressed 
children and adolescents. However, there is also recent evidence that selective serotonin 
reuptake inhibitors such as fluoxetine are efficacious, and they will likely play an 
increased role in the management of affective illness in youngsters. The clinical 
implications and limitations of these data are discussed and suggestions for future 
research are provided. 
(164 pages) 
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CHAPTER I 
INTRODUCTION AND PROBLEM STATEMENT 
Although childhood depression was not a recognized phenomenon until recently, 
it is now considered to be an important area of research in child psychopathology. Prior 
to its recognition, various researchers and clinicians questioned whether depression as a 
disorder could develop in children (Rie, 1966), or as described depressive equivalents 
( e.g., "masked depression") that were purportedly manifested by overt behavioral 
problems such as delinquency, hyperactivity, and aggression (Cytryn & McKnew, 1972; 
Glaser, 1967). However, based on current research, depressive disorders in children are 
indeed real phenomena (Kovacs, 1997). Depression in children, for the most part, is 
characterized and identified in many of the same ways as depression in adults (American 
Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders [4th ed.], 
1994; Kovacs , 1996), and it adversely affects the lives of many youth. 
Estimates of the prevalence of child and adolescent depression in the general 
population are substantial , ranging from 0.4% to 8.3% (Anderson, Williams, McGee , & 
Silva, 1987; Birmaher et al., 1996b; Fleming & Offord, 1990; Kashani et al., 1983; 
Lewinsohn, Clarke, Seeley, & Rohde, 1994). Among groups of clinically referred 
children, the prevalence rates are even higher (Poznanski & Mokros , 1994). Early-onset 
depression is often persistent and leads to an increased risk of recurrence during 
adolescence and adulthood (Kovacs, Obrosky, Gatsonis, & Richards, 1997). Further, 
depression in children and adolescents is associated with negative outcomes including: 
poor physical health, social and interpersonal impairments, academic problems, substance 
abuse, future maladjustment, and suicidal behavior. 
In light of the prevalence, persistence, and negative outcomes associated with 
depressive disorders in children, several researchers and clinicians have developed and 
implemented various treatments for childhood depression ranging from psychosocial 
interventions to pharmacological interventions. 
Although there are a number of good meta-analytic reviews that indicate that 
psychotherapy is generally effective with children and adolescents who present with a 
broad array of problems (e.g., Casey & Berman, 1985; Weisz, Weiss, Han, & Granger, 
1995), comprehensive reviews investigating the efficacy of psychosocial treatments for 
child and adolescent depression are currently nonexistent in the published literature . 
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In terms of pharmacological interventions for depressed youth, a number of open 
and controlled clinical trials have been conducted. In addition, the prescription of 
psychotropic medications for depression in children and adolescents has become a widely 
accepted practice. However, the efficacy and safety of such practices remain the subject 
of much debate and controversy, due to methodological problems, developmental 
considerations, and limited empirical support. Furthermore, there is a paucity of data on 
the comparison of pharmacological and psychosocial interventions for child and 
adolescent depression. 
Current reviews of the outcome studies for childhood depression have not been 
adequate for guiding research, policy, and practice because many of the reviews are 
narrative in nature, methodologically flawed, and/or present vague or conflicting 
conclusions. Furthermore, while some of the efforts to review and synthesize the body of 
3 
literature on the treatments for depressed youth have answered some questions, there are 
many more questions left unanswered. From clinical and empirical perspectives, it is 
important to know whether outcomes covary with study and sample characteristics. For 
instance, which types of treatments are the best and for whom? Does the age of the child 
matter? Do comorbid conditions impact the outcomes? Does it make a difference 
whether the children have been identified as suffering from depressive symptomatology 
as opposed to a depressive disorder? Are the findings from a school-based sample 
generalizable to a clinic-based sample? What is the overall efficacy of pharmacological 
treatments for child and adolescent depression? How do psychosocial interventions 
compare with pharmacological treatments? Is there evidence of differential efficacy 
when a number of important variables are considered ( e.g., age, sex, severity, 
methodological factors)? 
If a comprehensive, methodologically sound review of the literature on the 
efficacy of psychosocial and pharmacological treatments for childhood depression 
existed, researchers and clinicians would have a better understanding of which treatments 
are effective in ameliorating depressive symptomatology in children as well as how 
outcomes covary with study and sample characteristics . Furthermore, a more 
comprehensive review would help to guide both intervention efforts and future empirical 
studies on the treatment of depressive disorders in children. Therefore, in the present 
study, an integrative review of early-onset depression treatments was conducted. 
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CHAPTER II 
REVIEW OF RELATED LITERATURE 
The present literature review was conducted to establish support for the need to 
complete a comprehensive, methodologically sound review of the outcome studies on the 
psychosocial and pharmacological treatments of childhood depression. A definition and 
brief history of childhood depression are presented, followed by a review of the 
prevalence , longitudinal course, correlates, and the assessment and diagnosis of childhood 
depressive disorders. For purposes of clarity, the term "children" is used inclusively 
subsuming children and adolescents between 6 and 18 years of age. However , when age-
related distinctions are made, young children are referred to as those who are between 6 
and 12 years old, whereas adolescents are identified as those who are between the ages of 
13 and 18. Finally, a review of the current knowledge regarding the psychological and 
pharmacological treatment of childhood depression is included. 
Depression in Children 
As a symptom, depression is characterized by a dysphoric or unhappy mood state. 
Defined as a syndrome, depression consists of a constellation of behavioral and emotional 
symptoms that do not simultaneously exist by chance (Rehm & Tyndall, 1993). For 
example, when depressed mood is combined with labored psychomotor functioning, 
cognitive difficulties , and a lack of motivation, these symptoms, if experienced 
simultaneously , are often construed as evidence of a depressive syndrome. Establishing 
the existence of a depressive disorder depends largely upon the duration and severity of 
the symptoms as well as whether there is a pattern of marked impairment in important 
areas of functioning ( e.g., academic, social, physical). 
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From a historical perspective, there have been a limited number of empirical 
efforts to investigate depressive illnesses in children because until recently, most 
researchers and clinicians debated about the nature and existence of childhood depression 
(Kaslow & Rehm, 1991 ). Although today there is a general consensus among researchers 
and clinicians that childhood depression is similar to adult depression, three historical 
conceptualizations of depression in children contributed to the lack of previous empirical 
efforts in the area. First, based on the classic psychoanalytic viewpoint that was 
predominant during the early part of this century, depression could not exist in children 
because they lacked the mental structure (i.e., superego) necessary for the development of 
depression. Rie ( 1966) pointed out that a number of psychoanalysts believed that 
depression resulted from the discrepancy between the real self and the ideal self. 
However, based on this conceptualization, a stable self-representation does not develop 
until adolescence, and thus the major components of depression cannot develop during 
childhood . 
The second conceptualization of childhood depression, popular during the 1960s, 
included depressive equivalents or "masked depression," which were supposedly 
manifested by a variety of behavioral problems such as temper tantrums, hyperactivity, 
running away, learning disabilities, enuresis, and school failure (Cytryn & McKnew, 
1972; Glaser, 1967). The major criticism of this conceptualization was the fact that 
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virtually any behavioral problem could be construed as masked depression , which 
seriously hampered a clinician ' s ability to discriminate between depressive and 
nondepressive behavioral problems (Carlson & Cantwell, 1980). The third 
conceptualization of childhood depression worthy of mention was the notion that 
depressive symptoms (e.g., depressed mood) in children were merely transitory and not 
indicative of a depressive disorder (Lefkowitz & Burton, 1978). This position was most 
popular prior to the publication of American Psychiatric Association, Diagnostic and 
Statistical Manual of Mental Disorders (3rd ed.) in 1980, in which formally diagnosing 
children with depressive disorders was sanctioned by a number of professional groups 
(DSM-III, 1980). However , based on several longitudinal studies of children with 
depressive disorders , it is clear that these conditions are often more chronic and persistent 
than previously thought (e.g., Fleming , Boyle , & Offord , 1993; Hughes , Preskom , Wrona , 
Hassanein , & Tucker , 1990; McCaule y et al., 1993; McGee & Williams , 1988). 
Despite the aforementioned conceptualizations that challenged the legitimacy of 
depression in children , Kovacs (1989) suggested that there is now compelling evidence 
from several empirical studies that children suffer from depression , regardless of whether 
it is defined as a symptom ( depressed mood) , a syndrome ( constellation of symptoms) , or 
a disorder ( diagnosis based on the severity and duration of symptoms) as reflected in 
current nosological systems such as the DSM-IV , (1994). 
Prevalence and Longitudinal Course 
Prevalence estimates of child and adolescent depression are varied , ranging from 
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0.4% to 8.3% (Birmaher et al., 1996b; Garrison et al., 1997; Lewinsohn et al., 1994; 
Silver , 1988). Further, the prevalence estimates for depression in child samples are 
reportedly lower than in adolescent cohorts (Harrington , Rutter, & Fombonne , 1996). 
However, it remains unclear whether the lower prevalence rates in child samples are due 
to actual differences in prevalence or an artifact of how developmental differences ( e.g., 
language, self-understanding) might impact the assessment of depressive disorders in 
children (Cicchetti & Schneider-Rosen, 1986). In terms of sex differences in early-onset 
depressive disorders , it appears that males and females are equally affected during 
childhood (Birmaher et al., 1996b ). However , as young children move into adolescence, 
the prevalence rates begin to shift whereby adolescent females experience depressive 
sequelae at twice the rate of their male counterparts , a sex ratio that closely resembles that 
of adult samples (Cicchetti & Toth, 1998). 
In a critical evaluation of epidemiological studies of childhood depression , 
Fleming and Offord ( 1990) suggested that the variation in prevalence rates is due 
primarily to methodological flaws in the research designs including sampling bias, small 
samples , inconsistent measurements, age parameters, and diagnostic procedures. In light 
of these problems , the authors suggested that it is difficult to draw firm conclusions about 
the prevalence of childhood depression (Fleming & Offord, 1990). Nonetheless , even the 
lowest estimates are substantial , especially when one considers the long-term risk of 
depressive disorders in children and adolescents . For example, Kessler et al. (1994) 
reported that the lifetime prevalence of major depressive disorder (MDD) during 
adolescence is 15-20%, an estimate similar to adult samples . 
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The longitudinal course of childhood depression has received increased attention 
in the empirical literature over the last several years. Early studies characterized 
depressive disorders as transient, normal developmental reactions to stress and viewed 
them as unstable when compared to the relative stability of behavioral disorders (Fischer, 
Rolf, Hasazi, & Cummings, 1984; Graham & Rutter, 1973; McGee et al., 1985), 
especially conduct disorder (Offord et al., 1992). Clarizio (1984) posed the question of 
whether childhood depression is a chronic, transitory, or recurring condition . According 
to Clarizio, the answer depends on whether the sample under investigation is based upon 
a normal or clinical population, the severity and type of the depression, and how long the 
sample is followed. 
In addition, determining the longitudinal course of depression depends upon 
whether one is measuring depressive symptomatology or attempting to determine whether 
a depressive disorder is present. The specific depressive symptomatology can vary over 
time and the determination of whether a disorder is present may reflect a diverse array of 
symptom clusters that change in frequency and severity above and below a particular 
diagnostic threshold. Kazdin (1990) described this phenomenon as the distinction 
between dimensional (symptomatology) versus categorical (diagnostic) assessment. 
Despite the aforementioned considerations, several recent longitudinal studies have 
provided evidence to support the idea that depressive disorders are more persistent than 
previously thought (Kovacs, 1989). 
In one of the first longitudinal investigations of depressive disorders in children, 
Kovacs et al. ( 1984) reported that a significant number of youngsters remained 
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symptomatic for 5 years or more , even when treatment was implemented. In addition , 
McGee and Williams ( 1988) reported that 31 % of depressed 9-year-olds were found to 
have persistent depressive disorders after 2- and 4-year follow-ups , at the ages of 11 and 
13, respectively. In another longitudinal study, Nolen-Hoeksema, Girgus, and Seligman 
(1992) found that in a large sample of children who initially met criteria for serious levels 
of depression during initial testing, approximately 40% remained at that level for 6 
months to 2 years . 
Furthermore , DuBois , Feiner, Bartels , and Silverman (1995) investigated the 
course and stability of self-reported depressive symptoms in a community sample of 435 
school-age children . The authors reported that upon initial assessment , 10% of the 
sample presented with clinicall y significant symptoms of depression . Two years later , the 
authors reported that 32% of the "clinical " sample continued to endorse clinically 
significant levels of depressive symptomatology and evidenced a greater pattern of 
impairment across several areas of functioning. A number of other longitudinal 
investigations have augmented the notion that depressive disorders in children and 
adolescents are often characterized by a persistent , chronic course (e.g., Fleming et al. , 
1993; Kovacs , Akiskal , Gastonis, & Parrone , 1994; Kovacs et al. , 1997; Lewinsohn et al., 
1994). Thus , the findings from a number of empirical studies appear to contradict the 
belief that young children only suffer from brief and episodic depression, highlighting the 
importance of providing effective treatments early during the course of the illness . 
IO 
Correlates of Depression in Children 
Several researchers have asserted that depressive disorders in children typically 
result in significant distress , misery , and negative outcomes in young people including: 
diminished self-esteem (Kazdin , 1988), poor physical health (Costello et al. , 1988), 
family dysfunction (Kashani , Burbach , & Rosenburg , 1988), increased risk for substance 
abuse (Kovacs , Goldston , & Gatsonis , 1993), future psychological problems (Kovacs, 
1985), and a substantial risk for morbidity and mortality across the lifespan (Fleming & 
Offord , 1990; Harrington & Vostanis , 1995). There is compelling evidence that children 
and adolescents who suffer from depression have a variety of problems in daily living , 
ranging from unsatisfying interpersonal relationships (Puig-Antich et al., 1985) to 
noteworthy declines in academic perfom1ance (Fleming , Offord , & Boyle , 1989), and an 
increased risk for dropping out of school (Fleming & Offord , 1990). 
Furthermore , Puig-Antich et al. (1985) reported that depressed children had more 
severe family , peer-related , and social problems when compared to nondepressed 
controls . Kovacs (1997) suggested that "the social problems of depressed youngsters may 
be related to or derive from their interpersonal behavior and impact on others " (p. 288). 
That is, impaired social functioning, which is often associated with depression , may both 
contribute to and be caused by depressive sequelae. For example , in an observational 
study of children in a school setting , Altmann and Gotlib (1988) reported that while 
depressed children attempted to engage in social exchanges , they spent considerable 
amounts of time alone, thus limiting the amount of potentially reinforcing social contact 
and the opportunities to practice and develop age-appropriate social skills (Kovacs & 
Goldston, 1991). Similarly, Goodyer, Germany, Gowrusankur, and Altham (1991) 
reported that early-onset major depressive disorder interferes with the acquisition of 
problem-solving skills in children and adolescents. 
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In studies where the relationship between depression and impaired family 
functioning has been examined, greater amounts of conflict (i.e., marital , sibling, parent-
child) have been reported in families with depressed versus nondepressed youngsters 
( e.g ., Beck & Rosenberg , 1986; Kaslow, Rehm, Pollack, & Siegel , 1988). In addition , 
Kovacs (1997) suggested that the developmental, interpersonal, and social deficits 
associated with childhood depressive illnesses can have "ominous consequences in the 
context of family life by disrupting the attachment bond between parent and child" 
(p. 289). 
Another reason to be concerned about child and adolescent depression is the 
association between clinical mood disturbances and suicide (Bettes & Walker , 1986; Rao, 
Weissman , Martin , & Hammond , 1993). Kovacs et al. (1993) reported that depressive 
disorders were associated with significantly higher rates of suicide than were 
nondepressive disorders in a mixed sample of children between the ages of 8 and 13. In 
addition, Kovacs et al. ( 1993) found that "in the presence of affective disorders , comorbid 
conduct and/or substance abuse disorders further increased the risk of suicide attempts" 
(p. 8). 
In sum, depressive sequelae in children and adolescents are correlated with a 
plethora of impairments in developmental, intrapersonal, social , academic, and familial 
domains. These impairments, combined with the chronicity and likelihood of recurrence 
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of early-onset depression, provide ample justification for the need to develop, implement, 
and evaluate various interventions for depressed youth. 
Assessment and Diagnosis 
The efficacious treatment of virtually every psychological disorder is contingent 
upon an accurate assessment of the pathognomonic symptoms of that disorder 
(Achenbach, 1985) . In addition, the process of assessment can have a profound impact 
on treatment outcome studies because the assessment and diagnostic procedures are used 
to (a) guide the inclusion/exclusion of subjects and (b) provide the basis for pretreatment, 
posttreatment, and follow-up evaluations of treatment effects (i.e., dependent measures). 
Thus, it is crucial to attend to these assessment issues when attempting to accurately 
assess , diagnose, and ultimately treat child psychological sequelae . In the case of 
childhood depression, the historical lack of consensus regarding its nature and existence 
has hindered the establishment of consistent diagnostic criteria and has impeded the 
development of treatment regimens. However, when the American Psychiatric 
Association (1980, 1987) revised the DSM-III, DSM-IIIR during the 1980s, the diagnosis 
of depressive disorders in children was formally sanctioned. 
In the most recent version of the DSM-IV (APA, 1994), a diagnosis of either a 
depressive episode or a depressive disorder depends upon whether a minimum number of 
criteria (i.e., 5 out of 9) have been met. The criteria are made up of several emotional, 
cognitive, and behavioral symptoms, such as depressed mood, difficulty concentrating, 
changes in appetite, sleep disturbance, fatigue, thoughts of death, and impaired academic, 
interpersonal, and social functioning. While the authors of the DSM-IV (APA, 1994) 
suggested that 
the core symptoms of a Major Depressive Episode are the same for 
children and adolescents [ as they are for adults] ... certain symptoms such as 
somatic complaints, irritability, and social withdrawal are particularly 
common in children. (p. 324) 
Furthermore, Carlson and Garber (1986) suggested that developmental factors ( e.g., 
language, cognitive abilities, emotional insight) must be taken into account when 
attempting to identify and classify childhood depression. Nonetheless, Kovacs (1996) 
reported that there is evidence that depressive disorders "in childhood and in the later 
years of the life span capture the same psychopathological entity" (p. 711). 
Despite more consistent and professionally sanctioned diagnostic criteria, the 
accurate assessment and diagnosis of depressive disorders in children is complicated by 
several factors. First, there are a number of different methods for assessing depressive 
symptomatology in children including direct behavioral observation, behavior rating 
scales, sociometric approaches, clinical interviews, and self-report measures. Each of 
these methods has limitations. For example, Merrell (1994) reported that the evaluation 
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of childhood depression has typically relied upon the verbal or written reports of parents, 
teachers, and other significant figures in the child's environment "due to the supposedly 
questionable accuracy of information obtained through self-report methods" (p. 194). 
However, because depressive disorders are, in great measure, subjective perceptions of 
internal distress, they are often not readily or reliably identified by external observers (La 
Greca, 1990) and there is often disagreement among informants (Achenbach, 
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McConaughy, & Howell, 1987; Sanford, Offord, Boyle, Peace, & Racine, 1992). At the 
same time, the potential limitations of self-report measures include biased response styles 
(e.g., social desirability; Borg & Gall, 1989), children's inability to understand and report 
their emotions (Clarizio, 1984), and whether the instrument has an age-appropriate 
reading level (Prout & Chizik, 1988). In light of these issues, La Greca (1990) 
emphasized the importance of a multimethod-multisource assessment that takes into 
account, "the limitations inherent in any one procedure" (p. 8). However, from a 
historical perspective, assessment protocols utilizing multiple methods and multiple 
sources across settings have been the exception rather than the rule (Merrell, 1994). 
A second factor that complicates the assessment and diagnosis of depression in 
children is the fact that depressive disorders are a heterogeneous combination of symptom 
clusters that vary in presentation, duration, and severity from child to child (Cicchetti & 
Toth, 1998). Essentially, two different children can have the same diagnosis, but present 
with different manifestations of the disorder. For example, in order to meet the DSM-IV 
(AP A, 1994) criteria for a diagnosis of major depressive episode, an individual must 
present with a minimum of five out of nine criteria (i.e., symptoms) . It is conceivable 
that two children could be diagnosed with only a single common symptom. Therefore, 
both children can be diagnosed appropriately with major depressive episode; however, 
their manifestations of major depressive episode are quite different. Subsuming children 
with different symptom presentations into a broader diagnostic category leads to an 
inevitable loss of data regarding the true variability and unique symptom constellations 
presented across children suffering from depressive sequelae. Subsequently, treatment 
decisions might be based on broad assumptions about major depressive episode without 
considering the specific needs of individual children. 
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A third factor that complicates the assessment and diagnosis of depression in 
children is the issue of comorbidity. According to Stedman's Medical Dictionary (1995) 
comorbidity is defined as "a concomitant but unrelated pathological or disease process" 
(p. 174). For example, an individual might be suffering from both lung cancer and 
Hepatitis Bat the same time and thus be considered to have comorbid medical illnesses. 
These two disease processes are essentially independent of one another, with different 
etiologies, symptom presentations, and progression patterns. 
While the medical definition of comorbidity implies that illnesses are concomitant 
but unrelated, the use of the term comorbidity in the psychological and psychiatric 
literature is less well-defined. Unlike many medical illnesses, psychological disturbances 
are not discrete illnesses and are therefore more difficult to assess, diagnose, and classify, 
due, in part, to the overlapping nature of the various symptom clusters (Adams & 
Cassidy, 1993). For example, two disorders in the DSM-IV (APA, 1994), major 
depressive episode and generalized anxiety disorder, have overlapping diagnostic criteria 
including: irritability, difficulty concentrating, sleep disturbance, and fatigue (see Figure 
1 ). Consequently, children who present with these symptoms would meet some of the 
diagnostic criteria for MDE while simultaneously satisfying some of the diagnostic 
parameters of generalized anxiety disorder (GAD), thus making an accurate 
differentiation between the two diagnoses problematic. Angold and Costello ( 1993) 
stated that researchers and clinicians must evaluate whether patterns of comorbidity are 
I 
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Fatigue 
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Sleep Disturbance 
Figure 1. DSM-IV (APA , 1994) symptom overlap : major depressive episode and 
generalized anxiety disorder. 
"artifacts of the methods of data collection , data aggregation for diagnostic purposes , or 
the nosology itself ' (p. 1786). In sum, various authors have suggested that assessment 
methods should be broad enough (e.g., multiple instruments) to accuratel y identify 
several different constellations of symptoms , especially when there is evidence of 
comorbidity (Achenbach, 1985; Costello , 1986; Reynolds , 1992a, 1992b ). 
In spite of these diagnostic limitations , there is mounting evidence that the 
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existence of more than one psychological disorder in the same child is prevalent and can 
lead to poorer outcomes . For example, Offord et al. ( 1992) followed a community 
sample of over 1,000 children between 4 and 12 years old and reported that children with 
multiple disorders tend to "have a worse outcome years later compared with the single-
disorder group" (p. 921 ). In a more recent longitudinal study involving over 1,000 
children who were followed from birth to age 21, Newman et al. (1996) reported that 
nearly half of the subjects who evidenced a psychiatric disorder during the course of the 
study also had comorbid diagnoses at the age of 21. Further, the authors reported that 
"comorbidity was associated with severity of impairment" (p. 552). 
17 
Current comorbidity estimates for depression and anxiety in children range from 
15.9% to 61.9% (Brady & Kendall, 1992). Anderson et al. (1987) examined a 
nonclinical sample of 63 children and found that 15.9% qualified for both an anxiety 
disorder and a depressive disorder. However , Costello et al. ( 1988) reported much lower 
estimates of comorbidity in a nonclinical group of pediatric primary care patients , with 
coexisting symptoms of depression and anxiety appearing in 0.8% of the sample. In 
clinical samples, the comorbidity rates have been much higher. In a sample of 
hospitalized children , Carey, Finch , and Imm (1989) reported that 55.2% of the sample 
had diagnosable disorders of both depression and anxiety. Furthermore, Strauss, Last , 
Hersen, and Kazdin (1988) reported that in a group of outpatient children and adolescents 
who presented with anxiety disorders , 28.3% of the sample also met criteria for 
depressive disorders. 
Based on the aforementioned findings , there is a great deal of variation in the 
comorbidity estimates of depression and anxiety in children and adolescents. The 
variation has been attributed to "rather crude diagnostic criteria" (Angold & Costello, 
1993, p. 1786), unreliable data collection techniques (Garfield, 1993), similarity in self-
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report rather than construct overlap (Norvell , Brophy, & Finch, 1985), and the fact that 
depression and anxiety might be clinically related (Clark, Beck, & Stewart, 1990; 
Ollendick & King, 1994). Despite the discrepant findings, several authors have suggested 
that the overall comorbidity rates are large enough to be considered clinically meaningful 
(Kendall, Kortlander, Chansky, & Brady, 1992; Newman et al., 1996; Reynolds, 1992b). 
In sum, the assessment and diagnosis of depression in children is a complex 
process with a number of limitations. Nonetheless, it is incumbent upon researchers and 
clinicians to understand this process and to use the best methods available in order to best 
serve these children. In light of the variation in comorbidity estimates and the diverse 
presentation of symptom constellations, various researchers have recommended 
assessment practices that emphasize broad-band instruments and the solicitation of 
information from several sources (Achenbach et al., 1987; Finch & Rogers , 1984; 
Kazdin , 1988; Reynolds, 1992c ). Similarly, interventions may be differentially effective 
for various children (i.e., comorbid vs. no comorbid diagnoses); thus clinicians and 
researchers must remain mindful of these considerations when evaluating the efficacy of 
treatments. 
Summary 
Although childhood depressive disorders were not recognized until recently, it is 
now known that depression in children is a serious problem that has critical ramifications 
for a large number of young people. Depressive disorders typically result in a great deal 
of distress and suffering in children, which, for some, can lead ultimately to fatal 
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consequences in the case of suicide. In light of the prevalence , persistence , and serious 
consequences associated with childhood depression , mental health professionals have an 
obligation to provide expeditious and effective treatments to young people suffering from 
depressive disorders . 
Treatment of Childhood Depression 
Several treatments have been developed for depression in children ranging from 
group-based cognitive-behavioral interventions to pharmacotherapies . While there are a 
growing number of well-controlled clinical trials, most of the early attempts to document 
the efficacy of treatments for child and adolescent depression were based upon clinical 
experience , case reports , and extrapolations from the adult literature (Mueller & 
Orvaschel , 1997; Speier , Sherak , Hirsch , & Cantwell , 1995). In contrast , much more is 
known about the treatment of adult depressive disorders since a large number of well-
controlled clinical trials have been conducted , which in turn, have been integrated and 
summarized via meta-analytic studies (e.g., Robinson , Berman , & Neimeyer , 1990). In 
light of the paucity of clinical trials for child and adolescent depression relative to adult 
samples and the lack of any published , methodologically sound integrative reviews , the 
current state of knowledge regarding the efficacious treatment of childhood depression is 
unclear . This section includes a review of the adult and child literatures regarding the 
treatment of depression . 
Adult Literature 
A number of treatments for depression have been empirically studied and 
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validated for adult populations. For instance, the National Institute of Mental Health 
(NIMH) sponsored a large, multisite, controlled clinical trial that compared the efficacy 
of four treatments for adult depression, including imipramine plus case management 
(IMI-CM), a placebo plus case management (PLA-CM), and two types of psychotherapy 
(Treatment of Depression Collaborative Research Program; Elkin, 1994). The two types 
of psychotherapy implemented were cognitive-behavioral therapy (CBT) and 
interpersonal therapy (IPT). While there is some variation in the components of CBT, the 
ultimate goal of this therapeutic approach is to identify irrational and dysfunctional 
thoughts, become aware of how they lead to depressive feelings and behavior, and to 
modify thinking patterns (Beck, Rush, Shaw, & Emery, 1979). IPT, on the other hand, 
focuses on dysfunctional patterns of relating to others in a variety of social milieus with 
the main goal of identifying and modifying problematic interpersonal tendencies (Elkin, 
Parloff, Hadley, & Autry, 1985). In general, the findings indicated that either type of 
psychotherapy was as effective as medication and more effective than PLA-CM in 
reducing depressive symptomatology in a group of250 outpatient adults. Elkin (1994) 
reported that "there were ... no statistically significant differences between the two 
psychotherapies or between either of them and IMI-CM" (p. 119). 
Furthermore, there have been a number of large integrative reviews investigating 
the efficacy of various treatments for adult depressive disorders. For example, Robinson 
et al. (1990) conducted a comprehensive review of 58 controlled outcome studies of 
various psychotherapeutic treatments for adult depression ( e.g., cognitive-behavioral, 
psychodynamic, client-centered, pharmacologic). Based on their sample of studies, the 
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authors reported a standard mean difference effect size (ES; mean of the treatment group 
minus the mean of the control group divided by the control group or pooled standard 
deviation) of 0.74 when comparing psychotherapy clients and no treatment controls at 
posttreatment. This finding indicates that the average treated client was better off at 
posttreatment than approximately 77% of the untreated clients . Robinson et al. concluded 
that depressed adults derive substantial and long-lasting benefits from psychotherapy. 
They added that the benefits of psychotherapy were at least as effective as medication and 
that no specific type of psychotherapy was superior to another in assuaging depression in 
adult samples. Thus, important questions remain regarding what treatments are best for 
whom even with adults. 
Despite the fact that there are empirically supported methods of treating adult 
forms of depression , the generalization of these findings to children might be problematic 
in light of the developmental, cognitive, emotional, and age differences observed between 
adults and children (Speier et al., 1995). Yet, to a large extent, the adult literature has 
been used to guide the efforts to treat child and adolescent depression (Holmes & 
Wagner, 1992; Mueller & Orvaschel, 1997). While this extrapolation approach makes 
intuitive sense, making inferences from the adult literature to the child literature requires 
a leap of faith, a leap that has not been empirically validated to date. 
Child Literature 
While the psychotherapy literature for children and adolescents is not nearly as 
substantial as the adult literature, there have been a large number of treatment studies for 
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youth who present with a broad array of problems. Further, the results from several 
studies have been synthesized in large meta-analytic reviews of the overall efficacy of 
psychotherapy with children and adolescents. For example, Casey and Berman (1985) 
reviewed 75 studies published between 1952 and 1983 and reported a standard mean 
difference ES of O. 71, indicating that the average treated child scored better after 
treatment than approximately 76% of control-group children. However, there were no 
studies that specifically addressed depression in children. In another large meta-analytic 
review, Weisz, Weiss, Alicke, and Klotz (1987) examined the outcomes of 108 well-
designed treatment studies published between 1952 and 1983 involving children between 
the ages of 4 and 18 years of age. The authors reported a standard mean difference ES of 
0.79, indicating that the average child who received treatment was at the 79th percentile 
of control-group children. Kazdin, Bass, Ayers, and Rogers (1990) surveyed the 
published literature between 1970 and 1988 and included a broad sample of 223 studies 
in their analysis. When comparing treated versus untreated controls (64 studies), Kazdin 
et al. reported a standard mean difference ES of 0.88, indicating that the average child in 
the treatment group was better off at posttreatment than 81 % of the control-group 
children. However, the investigators in all of the aforementioned reviews did not 
specifically address the issue of treating child and adolescent depressive disorders or they 
collapsed "depression" studies into more broadly defined categories ( e.g., internalizing, 
emotional problems), making the extraction of specific data regarding the efficacy of 
depression treatment problematic. For example, Kazdin et al. (1990) categorized 16% of 
the original sample of 223 studies as treatment trials for "internalizing" problems ( e.g., 
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anxiety, withdrawal, emotional disturbances, depression) . 
Only one large published integrative review was located that addressed the issue 
of treating child and adolescent depression. In a meta-analytic review of 150 outcome 
studies on child and adolescent psychotherapy, Weisz et al. (1995) included six controlled 
outcome studies of child and adolescent depression and reported a standard mean 
difference ES of 0.64, indicating that the average child who received treatment for 
depression was better off than approximately 74% of children who did not. In a more 
recent investigation, Reinecke, Ryan, and DuBois (1998) analyzed many of the same 
studies (i.e., four of the six) included by Weisz, Weiss, et al. (1995) and included two 
others (i.e., Lerner & Clum, 1990; Wood, Harrington, & Moore, 1996) in a highly 
focused meta-analytic review of controlled cognitive-behavioral interventions for 
depressed adolescents. Reinecke et al. (1998) reported a standard mean difference ES of 
1.02, indicating that the average treated adolescent was better off at posttreatment than 
approximately 84% of the control subjects . Although the findings from these 
investigations are important, Weisz, Weiss et al. (1995) included only six studies and they 
did not specifically address how the outcomes of child depression studies might covary or 
interact with other variables (e.g., age, sex, type of treatment). In terms of the meta-
analytic review by Reinecke et al. (1998), the sample of studies analyzed were not only 
similar to a previously published meta-analysis, but the findings were limited in the sense 
that only cognitive-behavioral interventions for adolescents were included. Thus, the 
findings were far from complete. Essentially, one is left to ponder several important 
questions regarding the efficacy of psychosocial treatments for child and adolescent 
depression. For example, what treatments are the most effective and for whom? Does 
the age of the child make a difference? Do other variables such as length of treatment, 
therapist variables, and comorbid conditions make a difference? Is there differential 
efficacy for those suffering from depressive symptomatology versus a diagnosed 
depressive disorder? Furthermore, how do psychosocial interventions compare with 
pharmacological treatments? In sum, is there evidence of differential efficacy when a 
number of important variables are considered such as age, sex, severity, and 
methodological factors? 
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In one other systematic review worthy of mention, Black-Cecchini ( 1996) 
analyzed 13 outcome studies investigating the efficacy of group-based social skills 
interventions for depressed youth as part of an unpublished doctoral dissertation. By 
using meta-analytic procedures, Black-Cecchini reported that the social skills group 
interventions produced moderate to large effects (i.e., average ES 0.76) in terms of 
ameliorating depressive symptomatology in depressed children and adolescents primarily 
from school samples. Nonetheless, Black-Cecchini (1996) suggested that some of the 
outcomes covaried with certain design and sample characteristics. For example, Black-
Cecchini cross-tabulated the quality of the studies with the outcomes and found that 
"inferior" studies had the highest mean effect sizes when compared to the higher quality 
studies. In addition, Black-Cecchini noted that it was difficult to determine how other 
variables (age, ethnic status, type of treatment) covaried with the outcomes because either 
the data were not reported or the data were poorly defined or quantified. Further, Black-
Cecchini described some of the limitations found in the sample of outcome studies 
25 
including a paucity of investigations which included preadolescent samples (7-12 age 
group; N = 4) and an overreliance on self-report measures. In essence, Black-Cecchini's 
analysis provided some provocative ideas about the nature and course of the present 
study. 
Psychosocial Treatments for Childhood 
Depression 
As mentioned previously, a variety of psychosocial treatment regimens for 
depressed children have been described in the literature including: psychoanalytic, 
behavioral, familial, group, cognitive, relaxation, social skills training, problem-solving 
training, and multimodal therapies. For instance, in one case study, Frame, Matson, 
Sonis, Fialkor, and Kazdin ( 1982) used behavior therapy to treat a 10-year-old depressed 
child and reported that certain behavioral indices associated with depression ( e.g., 
suicidal gestures , labored psychomotor functioning) improved during the course of 
treatment and after a 12-week follow-up. Other investigators have reported similar 
results when using behavioral regimens to treat depressed youth ( e.g., Matson, 1982). 
In addition, some of the behavioral modalities are downward extensions of 
interventions originally intended for adults. For example, a behavioral method of treating 
depression in adults is based on the premise that depression results from low rates of 
environmental reinforcement, which is manifested by diminished activity levels (Costello, 
1972; Lewinsohn, 1974). Interventions designed to increase activity levels, especially 
pleasant activities, purportedly led to an increase in the amount of response-contingent 
reinforcement for clients, resulting in a decrease in depressive symptomatology (Kaslow 
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& Rehin, 1991). Furthermore, there is some evidence to support the efficacy of activity-
based regimens in adult depressives (e.g., Rehm & Kaslow, 1984). 
The relationship between pleasant/unpleasant activities and depression in youth 
has been examined empirically. In a sample of 8- to 14-year-old children , Wierzbicki and 
Saylor (1991) reported a positive correlation between elevated symptoms of depression 
and unpleasant activity levels. However, contrary to the authors ' predictions, they did not 
find a negative correlation between self-reported depressive symptomatology and pleasant 
activity levels. Although there have not been any depression treatment studies in child 
samples that adhere strictly to an activity-increase regimen, several empirical 
investigations have used activity-based interventions as part of the treatment protocol 
(e.g., Clarke et al., 1995; Kahn, Kehle, Jenson, & Clark, 1990; Lewinsohn , Clarke, Hops, 
& Andrews , 1990; Stark, Reynolds , & Kaslow, 1987). As such, it remains unclear as to 
whether these activity-based components contribute substantially to treatment efficacy. 
Similar to activity-increase regimens that are based on the idea that diminished 
reinforcement leads to depressive symptomatology , social skills models are premised 
upon the belief that underdeveloped or impaired social skills often preclude individuals 
from obtaining adequate social reinforcement that subsequently leads to depression 
(Rehin & Kaslow, 1984). Social skills training (SST) has been used to treat depression in 
children and adolescents. For example, Fine, Forth, Gilbert, and Haley (1991) compared 
a social skills training group and a therapeutic support group in the treatment of 
depression in adolescents . The authors reported that the therapeutic support group was 
more effective than the social skills group in ameliorating depressive symptoms in the 
adolescent sample at posttreatment , but that the modalities appeared to be equally 
effective after a 9-month follow-up. 
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In another study, King and Kirschenbaum ( 1990) reported that social skills 
training plus consultation was superior to consultation only in the prevention of 
depressive symptoms in a cohort of "at-risk" children between 5 and 11 years old . 
Furthermore , a number of other treatment studies involving depressed children and 
adolescents have included SST components in the intervention protocols ( e.g. , Clarke et 
al., 1995; Kahn et al., 1990; Lewinsohn et al., 1990; Liddle & Spence, 1990; Reynolds & 
Coats , 1986; Stark et al., 1987). However , questions remain about the degree to which 
social skills training components impact treatment outcomes . 
Other types of psychosocial interventions have been used in the treatment of 
child and adolescent depression including: aerobic exercise (Brown , Welsh , Labbe , 
Vitulli , & Kulkarni , 1992), relaxation (Kahn et al., 1990; Reynolds & Coats , 1986; Wood 
et al., 1996), psychoeducation (Clarke , Hawkins , Murphy , & Sheeber , 1993), and a 
combination of group and family therapy (Curry & Wells, 1998). The results from these 
studies have been mixed , with substantial differences in methodolog y, selection , and 
treatment procedures . Furthermore , Mufson et al. (1994) reported that a variant of IPT 
was efficacious in the treatment of early-onset major depressive disorder in a cohort of 
depressed adolescents . 
Perhaps the most common method of treating depressed youth in empirical trials 
is CBT, with the majority of studies favoring group over individual interventions. As 
mentioned above , cognitive-behavioral treatments are aimed at identifying irrational and 
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dysfunctional thoughts, enhancing awareness of how such thoughts lead to depressive 
feelings and behavior, and modifying thinking and behavioral patterns (Beck et al., 1979). 
In what is considered by many to be the seminal empirical study on the treatment of 
depressed youth, Butler, Miezitis, Friedman, and Cole ( 1980) compared role-play therapy, 
cognitive restructuring, and a wait-list control condition in a school-based sample of 56 
depressed children. The authors reported that both treatments were more effective in 
reducing depressive symptomatology than the wait-list control condition, with role-play 
therapy being slightly superior to cognitive restructuring. 
In another investigation, Reynolds and Coats (1986) conducted a group treatment 
study of child and adolescent depression with 30 moderately to severely depressed high 
school students. The investigators compared three treatment conditions including CBT, 
relaxation training, and a wait-list control group and reported that both active treatments 
resulted in significant improvements in depressive symptomatology when compared to 
wait-list controls at posttreatment and after a 5-week follow-up (Reynolds & Coats, 
1986). 
Furthermore, Weisz, Thurber, Sweeney, Proffitt, and LeGagnoux (1997) 
implemented a group-based, eight-session Primary and Secondary Control Enhancement 
Training program (see Rothbaum, Weisz, & Snyder, 1982 for further review) with 48 
children with mild-to-moderate depressive symptoms. Weisz et al. (1997) reported that 
the intervention was effective in reducing self-reported symptomatology at posttreatment 
and after a 9-month follow-up in comparison to control subjects. In addition, there is a 
recent trend of examining the efficacy of individual CBT in the treatment of depressed 
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youth with some promising results (e.g., Brent et al., 1997; Vostanis , Feehan, Grattan, & 
Bickerton, 1996; Wood et al., 1996). 
While the aforementioned studies provide us with important insights about the 
treatment of childhood depression, many questions are left unanswered. Based upon a 
general review of the literature, it is estimated that there are approximately 20-25 
empirical studies investigating the efficacy of psychosocial treatments for child and 
adolescent depression to date . However, there are important differences across the 
various studies ( e.g. , design , selection, outcome , number of subjects, setting , 
assessment/diagnostic strategies, therapist variables , age range, demographics , type , 
length, frequency , and intensity of treatment) . Thus, useful generalizations about which 
interventions would be the most effective and for whom are difficult to make based on a 
general review of the literature . These findings highlight the need to integrate the body of 
literature on the psychosocial treatments for childhood depression . 
Narrative Reviews 
Thus far, most of the efforts to review , integrate , and summarize the results of 
various psychosocial treatment outcome studies for child and adolescent depression have 
been inadequate for guiding research , policy, and practice because many of the reviews 
are narrative in nature , methodologically flawed, and/or present vague or conflicting 
conclusions. Thirteen narrative reviews were located, published between 1983 and 1998 
(Birmaher, Ryan, Williamson, Brent, & Kaufman , 1996a, 1996b; Clarizio , 1986; Cytryn 
& McKnew, 1985; Dujovne, 1993; Harrington , 1992; Holmes & Wagner, 1992; Kashani 
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& Cantwell, 1983; Kaslow & Thompson, 1998; Keller , Lavori, Beardslee, Wunder , & 
Ryan, 1991; Larsson, 1992; Petersen et al., 1993; Puig-Antich & Weston, 1983; 
Reynolds, 1990). The number of psychosocial treatment studies cited in the above 
mentioned reviews ranged from zero (Cytryn & McKnew , 1985) to 14 (Kaslow & 
Thompson, 1998). In terms of the substantive findings from the earlier reviews , they are 
often unclear and conflicting. For example, Clarizio (1986) provided a narrative review 
of the treatments for childhood depression, including behavioral regimens , cognitive 
strategies , pharrnacotherapy , family therapy, and multimodal therapy . In general , Clarizio 
suggested that there is evidence that many of these regimens are effective in ameliorating 
depressive symptomatology in children . However , Clarizio (1986) cited only s treatment 
studies in his review , he did not include any effect sizes , and he cautioned that "there are 
no easy answers " when choosing a treatment method for childhood depression. 
In another narrative review , Larsson (1992) concluded that "controlled 
investigations of psychological treatments have, to date , been carried out solely with 
school samples of children that suffer from moderate depression" (p. 12). Larsson cited 
seven treatment studies and he added that most of these treatments were based on 
cognitive-behavioral principles ( e.g., problem-solving , cognitive-restructuring). In 
addition , Larsson reported that despite the evidence that cognitive-behavioral 
interventions have been shown to be efficacious with school samples, investigations on 
the effectiveness of psychotherapy for depressed children from clinical populations are 
nonexistent. 
In more recent reviews of the treatments for child and adolescent depression , the 
31 
conclusions are neither compelling nor are they based on exhaustive surveys of the 
literature. Dujovne, Barnard, and Rapoff (1995) included approximately treatment 
studies in their review and concluded that "the efficacy of cognitive-behavioral treatments 
has not yet been consistently demonstrated because investigations have been sparse and 
lacking in methods of subject selection and assessment which could result in 
representative samples" (p. 606). Approximately one year later, Birmaher et al. (1996a) 
reviewed the previous years of literature on child and adolescent depression . While the 
authors cited more psychological treatments studies (i.e., 10) than previous reviewers, the 
survey was far from comprehensive and the authors did not systematically analyze how 
treatment outcomes might covary with important variables ( e.g., age, sex, severity of 
illness, treatment type). 
In perhaps the most systematic narrative review to date, Kaslow and Thompson 
(1998) reviewed 14 psychosocial interventions for child and adolescent depression. In 
general, the authors suggested that "psychosocial interventions are effective at 
posttreatment and follow-up in reducing depressive symptoms/disorders in clinical and 
nonclinical samples of youth, regardless of treatment modality or extent of parental 
involvement" (p. 146). However, Kaslow and Thompson (1998) examined the extent to 
which each of the studies conformed to guidelines proposed by the Task Force on 
Promotion and Dissemination of Psychological Procedures ( 1995) "for well-established 
and probably efficacious interventions" (p. 146). Briefly, the criteria for well-established 
psychosocial interventions for childhood disorders are: (a) at least two well-conducted 
group-design studies conducted by different research teams indicate the treatment is 
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superior to a pill placebo or an alternative treatment, or equivalent to an already 
established treatment; or (b) a large series of methodologically sound single case studies 
(i.e. , n > 9); (c) interventions where treatment manuals were utilized; and (d) clearly 
specified sample characteristics (Lonigan , Elbert , & Johnson , 1998). The criteria for 
probably efficacious psychosocial interventions for childhood disorders are slightly less 
stringent in that they do not require replication by two different research teams, the 
treatment must be more effective for experimental versus no-treatment control subjects , 
and the required number of methodologically sound single case designs was reduced (i .e., 
n > 3). In sum, Kaslow and Thompson (1998) concluded that only 2 of the 14 studies 
reviewed met the criteria for probabl y efficacious psychosocial interventions for 
childhood disorders (i.e., Stark et al., 1987; Stark, Rouse , & Livingston , 1991). In 
addition , the authors reported that not one of the reviewed studies met criteria for well-
established psychosocial interventions for childhood disorders . Thus , even the most 
recent reviews of the child and adolescent depression treatment literature leave many 
questions unanswered and unaddressed. 
In summary , published narrative reviews of the child and adolescent depression 
treatment literature are plentiful yet uncompelling in guiding policy , research, and 
practice . Further , in the reviews published to date, there has not been an attempt to 
collect and systematically compare a more comprehensive sample of treatment studies, 
including pharmacologic interventions. Thus, a more complete , systematic analysis of the 
child and adolescent depression treatment literature is clearly indicated . 
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Pharmacological Treatment 
The prescription of pharmacologic medications for depression in children has 
become a widely accepted practice (Kaplan, Simms, & Busner, 1994) despite the fact that 
the Food and Drug Administration (1994; FDA) has yet to approve a single psychotropic 
agent for the specific purpose of treating depressed youth up to the age of 1 7 years old 
(Physician's Desk Reference, 1998; Peter Jensen, personal communication, March 16, 
1998; Sommers-Flanagan & Sommers-Flanagan, 1996). The practice of using approved 
drugs for unlabeled conditions is common and does not prohibit physicians from such 
practices (American Academy of Pediatrics Committee on Drugs, 1996). Unapproved 
use of approved drugs does not necessarily imply disapproval or contraindication, only 
that the drug has not been studied adequately for a particular (i.e., unlabeled) condition. 
Before a drug can be approved for a specific problem, its safety and efficacy must be 
evaluated and the data submitted to the FDA. Realistically, this process can take several 
years, and thus physicians are often faced with challenge of balancing their clinical 
judgment with the available empirical literature at the time. The labeling of drugs "is 
intended neither to preclude the physician from using his or her best medical judgment in 
the interest of patients nor to impose liability for failure to comply with labeling 
restrictions" (American Academy of Pediatrics, 1996, p. 144). 
In cases of "off label" prescribing, Spencer, Wilens, and Biederman (1995) 
suggested that the "risks, potential benefits, and informed consent should be carefully 
documented" (p. 97). Thus, a drug's efficacy and its potential side effects must be 
carefully evaluated and reviewed with patients and their families before initiating a 
34 
medication trial. In the case of pharmacotherapy for child and adolescent depressive 
disorders, psychiatrists and pediatricians can choose from a variety of psychotropic 
medications including tricyclic antidepressants (TCAs) such as imipramine (Tofranil), 
amitriptyline (Elavil), desipramine (Norpramin), and selective serotonin reuptake 
inhibitors (SSRis) including fluoxetine (Prozac), paroxetine (Paxil), and sertraline 
(Zoloft). Other medications that have been prescribed for children and adolescents who 
present with atypical depression, treatment-resistant mood disorders, and bipolar forms of 
affective illness include monoamine oxidase inhibitors, mood stabilizers such as lithium 
or valproic acid, and anticonvulsants such as carbamezapine (Spencer et al., 1995). 
However, the types of psychotropic medications used most often for children who present 
with depression are TCAs and SSRis (Birmaher et al. 1996). 
It has been hypothesized that medications such as TCAs and SSRis act on the 
noradrenergic and serotonergic systems in the central nervous system by slowing the 
reuptake of particular neurotransmitters ( e.g., norepinephrine, serotonin) in the synaptic 
cleft, thus prolonging postsynaptic potentials (Kandel, 1991 ). Although several 
hypotheses regarding the action of antidepressant medications have been advanced over 
the past 30 years (e.g., catecholamine hypothesis), a compelling model of the exact nature 
of the pharmacologic mechanisms and the pathophysiology of depression remains elusive 
(Duman, Heninger, & Nestler, 1997). Recent empirical findings suggest that 
antidepressant medications impact brain physiology well beyond the neurotransmitter 
(i.e., monoamine) and receptor levels. For example, Duman et al. (1997) suggested that 
the "long-term, therapeutic action of antidepressant treatments is mediated by 
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postreceptor intracellular targets" (p. 598; see Duman et al., 1997 for a review). 
With regard to the safety of pharmacotherapy for child and adolescent depression, 
the potential adverse impact that pharmacologic interventions have on child development 
remains unclear (Antonuccio, Danton, & DeNelsky, 1995; Vitiello & Jensen, 1997). 
Further, there have been some serious concerns raised about treating children with TCAs. 
For example, Riddle, Geller, and Ryan (1993) reported that the sudden death of a child 
was associated with the cardiotoxic effects of the antidepressant medication desipramine. 
In addition, Werry (1995) seriously challenged the safety of using certain TCAs with 
children in light of their noxious side effects ( e.g., anticholinergic effects, sedation), and 
the increasing number of deaths associated with the use of certain TCAs in children. 
However, some authors have suggested that the association between TCAs and 
cardiotoxic effects in children remains unclear and should not necessarily preclude their 
use in juvenile patients (Wilens et al., 1996). With the advent of SSRis, which are known 
to have less noxious side effect profiles ( e.g., limited anticholinergic and sedative effects) 
and are easier to administer (i.e., once per day) than most of the TCAs, using SSRis might 
be a safer alternative to the use of TCAs for the treatment of child depressive disorders 
(Birmaher et al., l 996a). 
As mentioned previously, the practice of child and adolescent pharmacotherapy 
for depression makes sense in light of the strong parallels (i.e., syndromally and 
diagnostically) between child and adult manifestations of depressive sequelae (Ryan et 
al., 1987) and the empirical evidence that the use of psychotropic medications in adults 
suffering from depression is efficacious, with an average positive response rate between 
65% and 75% (Speier et al., 1995; Thase & Kupfer, 1996). In a recent revision of the 
FDA regulations (1994) regarding the establishment of efficacy for "pediatric use" of 
pharrnacologic agents , it was noted that extrapolations of drug efficacy from adults to 
children are justified provided that there is compelling evidence that "the course of the 
disease and the drug ' s effects are sufficiently similar in the pediatric and adult 
populations " (p. 64241 ). While there is evidence of psychopathological congruity 
between child and adult depressive disorders , Vitiello and Jensen (1997) cautioned that 
"similar treatment response cannot be inferred across the age groups based only on 
similar psychopathological or biological features" (p. 872). The authors added that 
despite the similarities in depressive phenomenology across the age groups , a 
"discrepanc y remains between the efficacy of tricyclic antidepressants in adults versus 
that in children" (p. 872, Vitiello & Jensen , 1997). 
Despite the equivocal status of treating child and adolescent depression with 
TCAs , early studies on the efficacy of antidepressant medication in child and adolescent 
samples appeared to be promising . Weinberg et al. initiated an open medication trial for 
34 depressed children , using either one of two TCAs , imipramine or amitriptyline 
(Weinberg , Rutman , Sullivan , Penick , & Dietz , 1973). The authors reported that 12 of 
the 19 children who received the medication evidenced "marked improvement " after one 
month. In contrast , it was reported that only 3 of the 15 children who did not receive the 
antidepressant medication evidenced clinical improvement after one month (Weinberg et 
al. , 1973). In another open trial , Puig-Antich , Blau, Marx , Greenhill, and Chambers, 
(1978) reported that six out of eight children evidenced a substantial reduction in 
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depressive symptomatology after eight weeks of treatment on imipramine. 
Other open medication trials appeared to be effective in ameliorating depressive 
symptoms in children as well ( e.g., Geller, Cooper, Chestnut, Anker, & Shuchter, 1986; 
Preskom, Weller, & Weller, 1982). However, as mentioned, these studies were open 
trials without control groups, double-blind conditions, or pharmacologically inert 
placebos. Thus, the positive findings were questioned on empirical grounds. That is, it 
was difficult to determine whether the observed improvements in the children were due to 
patient expectations (i.e., "placebo-effects"), measurement error, researcher bias, the mere 
passage of time, or other artifactual confounds . Placebo-controlled trials are of particular 
interest since a placebo effect is defined as "a beneficial effect. .. that arises from the 
patient's expectations concerning the treatment rather than from the treatment itself' 
(Stedman's Medical Dictionary, 1995, p. 644). In antidepressant trials for adult samples, 
Morris and Beck (1974) reported that the placebo response rates ranged between 30% and 
35%, which is generally considered to be an average placebo effect for antidepressants 
(Burke & Preskom, 1995). 
In light of the aforementioned methodological criticisms of open studies, a 
number of randomized, placebo-controlled medication trials for child and adolescent 
depression were designed and implemented. For example, Puig-Antich et al. initiated a 
placebo-controlled imipramine trial in a sample of 42 depressed children between the 
ages of 6- and 12-years-old (Puig-Antich et al., 1978). The authors reported a higher 
response in the placebo condition (68%) than in the active medication condition (56%). 
These findings were somewhat troubling since they contradicted the previous "evidence" 
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of antidepressant efficacy in children reported from the open trials. Kye and Ryan (1995) 
reviewed nine randomized, double-blind, placebo-controlled antidepressant trials in child 
and adolescent samples. The authors reported that only one study (i.e., Preskorn, Weller, 
Hughes, Weller, & Bolte, 1987) provided evidence that pharmacotherapy was superior to 
placebo in ameliorating depressive symptomatology in a group of 22 children between the 
ages of 6 and 12 years old. Further, Kye and Ryan (1995) cautioned that the evidence of 
efficacy in the study by Preskorn et al. was "clinically small but statistically significant" 
(p. 268). Preskorn et al. (1987) reported that the improvement from baseline was 43% in 
the active medication condition and 35% in the placebo condition. 
Only one published meta-analytic study was located in which the placebo-
controlled, double-blind trials using TCAs in the treatment of depression in children and 
adolescents were reviewed. Hazell, O'Connell, Heathcote, Robertson, and Henry (1995) 
reviewed 12 randomized, controlled trials comparing the efficacy of TCAs and placebo in 
depressed children between 6 and 18 years of age. The authors reported a standard mean 
difference ES of 0.35 for the active medication conditions versus the placebo ( control) 
conditions. Hazell et al. (1995) concluded that "the small additional effect afforded by 
treatment in comparison with placebo is unlikely to be clinically important in most 
patients" (p. 899). However, according to the authors, they were only able to derive 
effect sizes from 6 of the 12 studies due to limited information contained in the articles. 
Thus, some authors have criticized the conclusions from this meta-analytic review on 
empirical grounds ( e.g., Anderson, 1995). Furthermore, in a review of the drug trials for 
early-onset depression, Conners (1992) cautioned that "various methodological problems 
limit the conclusions that can be drawn" regarding the efficacy of antidepressant 
medications (p. 11 ). That is, the substantial differences in the measurements used, 
criteria for "improvement," selection procedures, and sample characteristics in the 
various studies render comparisons across the studies tenuous at best (Conners, 1992). 
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Although the literature regarding the use of TCAs in the treatment of child and 
adolescent depression has been either discouraging or equivocal, there have been several 
recent studies involving the use of SSRis with promising results. In a retrospective 
review of the medical records of 31 children between 9 and 18 years old who were 
hospitalized for depression, Jain, Birmaher, Garcia, Al-Shabbout , and Ryan (1992) 
reported that after a mean treatment duration of 35 days on fluoxetine, clinical 
improvement was seen in 74% of the patients as measured by the Clinical Global 
Impression Scale. In another retrospective review, Tierney, Joshi , Llinas, and Rosenberg 
(1995) evaluated the efficacy of sertraline in a group of 33 children and adolescents 
between the ages of 8 and 18 years old. The authors reported that the majority of the 
children evidenced significant improvement based on the indices of Clinical Global 
Impression Scales after the 10th week of treatment (Tierney et al., 1995). Moreover, 
open trials with fluoxetine have reportedly produced a significant reduction of depressive 
symptomatology in child and adolescent patients as well (e.g., Boulos, Kutcher, Gardner, 
& Young, 1992; Collie, Belair, Difeo, Weiss, & LaRoache, 1994 ). 
In addition to retrospective reviews and open trials, the results from several 
controlled studies involving the use of SSRis in child and adolescent samples have been 
published recently. Simeon, Dinicola, Ferguson, and Copping (1990) conducted a study 
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in which 40 adolescents between 13 and 18 years old participated in a placebo-controlled, 
double-blind study of fluoxetine treatment for depression. The authors reported that 
"fluoxetine was superior to placebo on all clinical measures except for sleep disorder, but 
the differences were not statistically significant" (Simeon et al., 1990, p. 71). In another 
trial, Mandoki, Tapia, Tapia, and Sumner (1997) evaluated the efficacy of venlafaxine 
(Effexor) in a cohort of 33 children and adolescents who met the DSM-IV (APA, 1994) 
criteria for major depressive disorder. The two treatment conditions consisted of 
venlafaxine and psychotherapy or placebo and psychotherapy. The authors reported that 
significant improvements were observed in both conditions, but they were reluctant to 
attribute the positive effects to venlafaxine drug therapy (Mandoki et al., 1997). 
However, in a recently published controlled trial of 96 children and adolescents being 
treated with fluoxetine , Emslieet al. (1997) reported a positive response rate of 56% in the 
active condition compared to a 33% positive response rate for those taking placebo. 
Thus, it appears that there have been some recent positive findings regarding the efficacy 
of SSRis in children and adolescents with depressive disorders. 
Overall, it is estimated that there are between 14-17 published studies 
investigating the efficacy of psychotropic medications for depressed youth. A more up-
to-date comprehensive review that integrates the recent studies and includes a systematic 
analysis of some of the important variables associated with outcome ( e.g., length of 
treatment, outcome measures) might provide some answers to important questions related 
to the efficacy of pharmacotherapy for child and adolescent depression. Furthermore, 
there is a paucity of data on the comparison of pharmacological and psychosocial 
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interventions for depressed children and adolescents. Only two studies were located that 
compared psychotherapy versus pharmacotherapy in the treatment of early-onset 
depression. In one of the studies (Mandoki et al., 1997, cited above), a sample of 
adolescents with major depression were treated with either venlafaxine and 
psychotherapy or pill placebo and psychotherapy. Although both treatments appeared to 
ameliorate depressive symptoms to a substantial degree, Mandoki et al. ( 1997) reported 
that "there was not a significant difference in improvement between both groups, which 
indicates that the medication treatment did not contribute significantly to the 
improvement" (p. 153). In the only other study located that compared psychosocial and 
pharmacological interventions , Dujovne (1993) treated six clinically depressed children 
between the ages of 8 and 11 with imipramine and cognitive-behavioral therapy in a 
multiple-baseline, crossover design. Dujovne (1993) reported that both treatments 
resulted in a significant reduction in depressive symptoms over the course of the study 
with a slight advantage to the cognitive-behavioral regimen and increased parental 
satisfaction of the nonpharmacologic intervention (i.e., cognitive-behavioral therapy). 
However, the author cautioned that four of the six children evidenced noxious side-
effects while taking the imipramine and the medication was discontinued. In sum, it 
appears that there are some important questions to be answered regarding the comparison 
of psychosocial and pharmacological interventions for depressed youth. The most 
compelling question seems to be whether pharmacotherapy should be the first-line 
treatment for children and adolescents who present with depression when 
nonpharmacologic interventions may be just as effective and do not expose the patient to 
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potentially noxious, if not dangerous side-effects. 
Summary 
In summary, a number of treatments for childhood depressive disorders have been 
developed ranging from pharmacotherapy to psychosocial regimens and it is estimated 
that there are approximately 40-50 studies investigating the efficacy of interventions for 
depressed youth. What we do know about the efficacy of psychosocial treatments for 
childhood depression is limited. There is moderate support for the efficacy of school-
based group interventions for children and adolescents who evidence depressive 
symptomatology on self-report measures . However, beyond this, there is not much else 
that can be said about empirically validated psychosocial interventions for childhood 
depression . In terms of pharmacologic interventions , it appears that TCAs have not been 
found to be superior to placebo in the majority of controlled outcome studies. There have 
been some recent studies of the efficacy of TCAs and SSRis in the treatment of children 
with depression, but these findings have yet to be integrated into a comprehensive 
literature review. Although some of the efforts to review and synthesize the body of 
literature on the treatments for depressed youth have answered some questions , there are 
many more questions left unanswered. For instance, which variables need to be 
considered? Do outcomes covary with study and sample characteristics? Which types of 
treatments are the best and for whom? Does the length of treatment impact outcomes? 
Does the age of the child matter? Do comorbid conditions impact the outcomes? Does it 
make a difference whether the children have been identified as suffering from depressive 
symptomatology as opposed to a depressive disorder? Are the findings from a school-
based sample generalizable to a clinic-based sample? 
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If a comprehensive, methodologically sound review of the literature on the 
efficacy of psychosocial and pharmacological treatments for childhood depression 
existed, researchers and clinicians would have a better understanding of which treatments 
are effective in ameliorating depressive symptomatology in children as well as how 
outcomes covary with study and sample characteristics. Furthermore, a good integrative 
review would help to guide both intervention efforts and future empirical studies on the 
treatment of depressive disorders in children. 
Treatment Variables 
As mentioned previously, there are several variables that must be considered 
when evaluating whether treatments for depression are effective for children. Central to 
question of treatment effectiveness is: What treatments are effective for whom and under 
what conditions? Ultimately , clients are best served when there is a proper fit between 
the client, the therapist, and the intervention. For example , if an 11-year-old, moderately 
depressed boy presents for treatment, what is the recommended course of treatment? 
Based on some of the empirical findings , one might recommend a school-based group 
intervention such as the Primary and Secondary Control Enhancement training proposed 
by Weisz et al. (1997) . Further, it could be argued that a prerequisite client variable for 
this type of treatment is an adequate level of intellectual functioning in light of the 
cognitive underpinnings of Primary and Secondary Control Enhancement training. 
However, suppose the child is cognitively impaired, thus precluding him from 
participating effectively during the treatment group? What if the child were an 8-year-
old, severely depressed female youngster? In other words, what can we say about the 
differential effectiveness of various treatments in light of some of these important 
variables? 
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Because a major thrust of this investigation is based upon how treatment study 
variables moderate outcome, several important variables will be defined and described in 
the following section, including age, sex, referral source, treatment setting, type of 
treatment, treatment variables, assessment measures, therapist variables, severity of 
illness, and comorbid conditions. In addition, available information on how the 
aforementioned variables impact treatment outcomes will be reviewed 
An important variable to consider when selecting the best course of treatment for 
depression is the client's age. As mentioned previously, certain therapies might be 
inappropriate for very young children such as certain cognitive regimens that might 
presuppose a particular level of cognitive development (e.g., formal operations, Piaget & 
lnhelder, 1969). No published studies were located that addressed specifically, the 
potential interaction between age and the treatment of early-onset depression (i.e., 
adolescent vs. child samples). Yet some interventions target one age group or another 
(e.g., Coping with Depression Course for Adolescents; Clarke, Lewinsohn, & Hops, 
1990). In addition, the empirical findings on the relationship between a child's age and 
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general psychotherapy outcome have been equivocal. For example, Weisz et al. (1987) 
conducted a meta-analysis of 108 treatment studies regarding the overall effectiveness of 
psychotherapy with children and adolescents. The authors reported that "therapy proved 
more effective for children (ages 4-12) than for adolescents (ages 13-18)" (p. 542). 
Weisz et al. reported that the mean effect size for therapy involving children was 0.92 as 
compared to 0.58 for adolescent clients. 
In contrast, Weisz, Weiss, et al. (1995) completed another integrative review (150 
different studies) of the effects of psychotherapy with children and adolescents and 
reported that "treatment outcomes were better for adolescents than for children" (p. 461). 
For children 11 and younger, the authors reported a mean effect size of 0.48, whereas the 
mean effect size was 0.65 for adolescents 12 and older. While it is unclear whether the 
differential inclusion criteria (i.e., "children" defined as 4-12 in Weisz et al., 1987 as 
compared to 11 and younger in Weisz, Weiss, et al., 1995) impacted the mean effect size 
calculations, the differential findings leave many questions unanswered . However , 
Weisz, Weiss, et al. ( 1995) suggested that the changes in age effect might be attributable 
to improvements in the effectiveness of adolescent interventions. In any case, the 
relationship between age and outcome remains unclear, especially with respect to the 
treatment of child and adolescent depression. 
The interaction between sex and therapy outcome has been investigated by several 
researchers who have conducted large meta-analytic reviews ( e.g., Casey & Berman, 
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1985; Weisz, Weiss, et al., 1995). Taken together, the findings suggest that 
psychotherapy is generally more effective for females than males. Weisz et al. (1987) 
reported a mean effect size of 1.11 for female majority groups and 0.80 for male majority 
groups. Weisz, Weiss , et al. (1995) reported similar findings , indicating that the mean ES 
for female samples was 0.71 as compared to 0.43 for male samples. In addition, the 
authors reported an age/sex interaction wherein the mean ES was 0.86 for adolescent 
female majority samples as compared to 0.37 for adolescent males. In contrast, the mean 
effect sizes for the male and female child samples (i.e., 11 and younger) were 
approximately equal. Thus , while there have been some interesting findings to date, more 
information is needed to better understand the relationship between sex and depression 
treatment outcome. 
Referral Source 
How a child or adolescent is referred for treatment is an important variable to 
consider when evaluating outcome. For example , has the child been clinically referred 
for treatment due to presenting symptomatology? Or, has the child been recruited by a 
research team and therefore volunteers to participate as an analog subject? Assuming the 
treatment is shown to be effective in ameliorating certain symptomatology in volunteer 
research subjects , the crucial question is whether the "effectiveness" is generalizable to 
actual clinical cases which may be more difficult to treat successfully. Weisz , Donenberg, 
Han, and Kauneckis (1995) reported that 
it is certainly possible that clinic-referred children are more seriously 
disturbed, that they come from more dysfunctional families, or that they 
are more likely to confront stressful life circumstances ( e.g., low income 
levels) than are the often middle class youngsters whose parents give 
consent for their participation in research studies. (p. 96) 
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Nevertheless , Weisz, Donenberg, et al. (1995) addressed this question empirically 
by comparing the mean effect sizes of clinic and analog samples from two large meta-
analytic reviews and reported that the differences were not statistically different. Further , 
based on the results from one of the meta-analyses (i.e., Weisz et al., 1987), the mean 
effect size of the analog samples (0.76) was smaller than the clinic samples (0.89), 
indicating that overall , psychotherapy was slightly more effective in treating clinical 
samples . Thus, the findings to date have been inconsistent regarding the impact of 
referral source on treatment outcome . 
Treatment Setting 
The setting in which psychotherapy is conducted is thought to have important 
implications for therapy outcome (Brent et al., 1997; Weisz, Weiss, & Donenberg , 1992). 
Treatment is conducted in variety of environments including inpatient units ( e.g., 
hospitals) , schools , outpatient clinics, private practice, research laboratories , and 
correctional settings . Some authors have suggested that treatment delivered during the 
course of everyday clinical practice as opposed to research or laboratory settings differs in 
important ways (Seligman , 1995). Clarke (1995) outlined a distinction between "efficacy 
investigations " and "effectiveness research." According to Clarke, efficacy investigations 
are controlled laboratory studies, whereas effectiveness research are clinical studies 
carried out in "broader mental health services systems" (p. 718). While Clarke lamented 
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how little attention is paid to how the results from controlled clinical trials generalize to 
applied clinical settings , some investigators have examined this issue . 
Weisz et al. (1992) found evidence that controlled research trials tended to 
produce better treatment outcomes than treatment provided in everyday applied clinical 
settings . However, the authors cautioned that their findings were based on relatively few 
clinic studies and that the studies had some methodological problems in comparison to 
the more rigorous and tightly supervised controlled trials. In addition, Kazdin (1990) 
suggested that there are major discrepancies between research treatment and clinical 
practice which make the extrapolation of the findings from one setting to the other 
problematic. According to the authors, the problem of generalizability may be 
attributable to factors such as problem foci and the severity of presenting problems. 
Further , Kazdin (1990) noted that the majority of treatment studies solicit children from 
school settings and provide treatment in groups , whereas clinically referred children in 
everyday clinical practice are seen usually on an individual basis. 
Furthermore, other investigators have examined whether other variables related to 
research and clinical settings had differential effects on therapy outcome. For example , 
Weisz , Donenberg , et al. (1995) questioned whether there is something about clinical 
settings that undermine the effectiveness of psychotherapy for children ( e.g., heavy 
caseloads, not problem-focused, not as strictly supervised). The authors found evidence 
that three factors contributed to the "superior" findings found in analog studies including: 
(a) the prevalent use of behavioral and cognitive-behavioral methods; (b) a reliance on 
focused, specific therapy techniques; and ( c) the provision of structured supervision and 
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monitoring (e.g., protocol adherence, reliability checks) throughout the trial. 
In sum, it appears that certain aspects of the treatment setting have the potential to 
moderate outcome based on general reviews of the child and adolescent psychotherapy 
literature. However , it remains to be seen whether some of the aforementioned issues 
have an impact on interventions for child and adolescent depression. 
Type of Treatment 
A major thrust of this investigation focuses on the relative effectiveness of various 
treatments for childhood depression. As mentioned previously, several treatments have 
been developed and implemented for childhood depression including but not limited to 
psychodynamic , cognitive-beha vioral, behavioral , problem-solving, relaxation , social 
skills training , activity-based , self-control training , interpersonal psychotherap y, family 
therapy , and pharmacotherap y. However, it appears that no single treatment is clearly 
superior to the others in ameliorating depressive symptomatolog y in children . In 
addition , there are those who suggest that most treatments are virtually equivalent in 
terms of therapeutic benefit. For example , Rehm (1995) suggested that we abandon the 
"horse race" comparisons between treatments for depression in adults in light of the fact 
"that comparison between any two such programs is unlikely to produce important 
differences in effectiveness" (p. 203) . In evaluating the overall effectiveness of 
psychotherapy , the equivalency of outcome from a variety of treatment methods has been 
referred to as the "dodo verdict" (Parloff, 1984 ). While there is some support for the 
dodo verdict in terms of the efficacy of various forms of psychotherapy for adult 
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depression and other disorders ( e.g., Robinson et al., 1990; Smith, Glass, & Miller, 1980), 
it remains unclear whether this so-called dodo verdict is applicable to psychotherapy for 
child and adolescent depression. 
For example, three large meta-analytic reviews provided some support for the 
idea that behavioral treatments are more effective than nonbehavioral methods in treating 
a variety of child and adolescent psychopathology (Casey & Berman, 1985; Weisz et al., 
1987; Weisz, Weiss, et al., 1995). However, the issue is far from settled as some authors 
have suggested that the differential effects are attributable to artifactual explanations such 
as methodological differences between studies ( e.g., Shirk & Russell, 1992). However , 
Weiss and Weisz (1995) reported that there was "little support" for such a hypothesis. In 
any case, there is empirical evidence to justify the comparison of various treatments for 
child and adolescent problems in light of the aforementioned findings. Further , little is 
known about the differences between behavioral versus nonbehavioral treatments for 
childhood depression in particular and how these variables interact with factors ( e.g., age-
related developmental changes) . 
Other Treatment Variables 
The actual length (i.e., weeks) and frequency (i.e., number of sessions) are 
important variables to consider when evaluating treatment outcome. An intuitively held 
assumption in psychotherapy research is that "more therapy is better." Historically, this 
assumption has played out in professional practice as the average duration of treatment in 
clinical settings (27-55 weeks) is substantially longer than it is in research or laboratory 
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settings (8-10 weeks; cf. Kazdin et al., 1990). However, in light of the present political 
and financial climate (i.e., cost containment, managed care), the need for empirically 
validated yet brief interventions for various psychological problems has never been 
stronger (Weisz et al., 1997). Furthermore, the intuitive assumption that more therapy is 
better has not been empirically supported (Weisz, Donenberg , et al., 1995). In light of the 
limited data on this issue, there is a need to better understand the relationship between 
various treatment variables (e.g., length , frequency) and the effectiveness of treatment for 
child and adolescent depression (Clarke, 1995). 
Assessment Measures 
As mentioned previously , the process of assessment can have a significant impact 
on treatment outcome studies because the assessment and diagnosti c measures that guide 
the inclusion and evaluation of subjects are used to determine whether the treatment is 
efficacious or not. There are a number of methods for assessing depression in youth 
including : behavioral observations , behavior rating scales ( e.g ., Child Behavior Checklist 
CBCL ; Achenbach & Edelbrock , 1983), sociometric approaches , diagnostic interviews , 
and self-report measures , the latter two of which are the most prominent. Several 
excellent self-report measures have been developed such as: the Children's Depression 
Inventory (CDI; Kovacs, 1992), the Mood and Feelings Questionnaire (MFQ ; Angold , 
Costello, Pickles , & Winder, 1987), the Reynolds Child Depression Scale (RCDS; 
Reynolds , 1989), the Center for Epidemiological Studies - Depression Scale (CES-D; 
Radloff, 1977), the Reynolds Adolescent Depression Scale (RADS; Reynolds, 1987), and 
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the Beck Depression Inventory (BDI ; Beck & Steer, 1987). Some of the more prominent 
diagnostic interviewing formats include the Schedule for Affective Disorders and 
Schizophrenia for School-Aged Children (K-SADS; Puig-Antich & Chambers , 1978) , the 
Children ' s Depression Rating Scale (CDRS ; Poznanski & Mokros , 1996), the Bellevue 
Index of Depression (BID ; Petti , 1978), and the Diagnostic Interview for Children and 
Adolescents-Revised (DICA-R; Reich & Welner, 1988). 
Nonetheless , many investigators ( e.g., La Greca , 1990) have stressed the 
importance of a multimethod protocol in light of the limitations of any one particular 
measure. At the same time , this process is often more the exception than the rule , and 
there has been a historical overreliance on a limited number of devices to evaluate 
depression treatment efficacy. For example , Black-Cecchini ( 1996) reported that of the 
13 treatment studies reviewed , 5 studies relied exclusively on one self-report device to 
determine efficacy . Further , of the 8 studies that used interview formats , sufficient data 
to calculate effect sizes were available in only 4 of the studies . 
Similarly , there is empirical evidence that depressive symptomatology , as 
measured by self-report instruments , attenuates over time , and repeated administrations 
(e.g ., Finch , Saylor , Edwards , & Mcintosh , 1987; Michael & Merrell , 1998). This 
attenuation phenomenon has been interpreted in several ways including: (a) an over-
endorsement of symptomatology by distressed children upon initial testing (Reynolds, 
1986); (b) an expected variation in reported symptomatology due to natural fluctuations 
in mood over time (Kovacs , 1992); and/or (c) a better understanding of the assessment 
task during subsequent intervals (Michael & Merrell , 1998). 
53 
In sum, it is vital to consider the impact that the measurement technology has 
upon the determination of treatment efficacy in light of the aforementioned data. While it 
seems apparent that there is a significant relationship between assessment and treatment 
outcome, there is a need to examine this relationship in-depth. 
Therapist Variables 
Therapist variables such as level of training, years of experience , and professional 
discipline have long been considered important when evaluating therapy outcome 
(Kazdin et al., 1990; Stein & Lambert , 1984). For example, Weisz et al. (1987) reported 
a significant interaction between level of training and client age, with paraprofessionals 
and graduate students being more effective with children as opposed to adolescent clients. 
In contrast, profes sional therapists were equally effective with both groups (Weisz et al., 
1987). In addition , Weisz et al. reported that professional therapists were somewhat more 
effective than their less trained counterparts (i.e., graduate students , paraprofessionals) 
with "overcontrolled " problems such as phobias and shyness. In a more recent 
investigation , Stein and Lambert (1995) conducted a meta-analysis of outcome studies 
involving within-study comparisons of therapists with different levels of training and 
experience . The authors concluded that "a variety of outcome sources are associated with 
modest effect sizes favoring more trained therapists" (p. 182). However , both Weisz et 
al. and Stein et al. cautioned that it is markedly difficult to come up with an accurate 
coding scheme to account for all the variables associated with differential training levels 
across a diverse array of studies ( e.g., graduate students being supervised closely by 
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experienced professionals) . Therefore, such methodological problems pose a significant 
threat to the validity of these findings. In sum, although there is growing evidence that 
increased levels of training are associated with greater levels of improvement, it is 
unsettling that "more compelling evidence is not available that demonstrates that graduate 
training directly relates to enhanced therapy outcomes" (Stein & Lambert, 1995, p. 194). 
Further, despite some provocative findings , it is unclear whether these trends are evident 
in the treatment of early-onset depression. 
Severity of Illness and Comorbiditv 
As mentioned previously, childhood depression is neither a discrete nor a 
homogeneous problem . It varies greatly in both the type and severity of symptom 
presentation . However , in treatment outcome research , there is usually a specific disorder 
or symptom that is identified as the dependent variable targeted for change (Hoagwood , 
Hibbs , Brent , & Jensen , 1995). An important question that needs to be addressed is : Does 
the type and severity of symptom presentation affect outcome? 
Furthermore , in clinical settings , depression is often only one of many clinical 
syndromes (e.g. , anxiety) that may be present in the same individual. A number of 
potential treatment subjects are often excluded from empirical studies if they present with 
a variety of comorbid conditions or symptoms even though this is common in everyday 
clinical settings (Clarke , 1995). These factors can make generalizations from the 
empirical literature to clinical practice problematic (Hoagwood et al., 1995). Hoagwood 
et al. (1995) suggested that treatment research needs to adapt to the "real life" situations 
that are encountered in clinical practice by considering some of the these important 
variables such as comorbidity . In general, it would be important to consider whether 
various treatments for depression are impacted by or have an impact upon, comorbid 
conditions. 
Quality of Study 
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Various authors have suggested that the quality of a study can impact not only the 
findings from a particular study, but also the overall findings from an integration or meta-
analytic review of several studies (e.g., Wilson & Rachman, 1983; Wortman, 1983). 
Wilson and Rachman (1983) hypothesized that methodologically weaker studies might 
skew the results from integrative reviews in the direction of an overestimation of therapy 
effects. Some aspects of how methodological variables impact ES calculations were 
examined in the one of the seminal meta-analyses of psychotherapy outcome (Smith et 
al., 1980). However , Smith et al. did not find compelling evidence that, for example , 
poor quality studies produced spuriously larger effect sizes in comparison with more 
methodologically rigorous studies. With regard to child psychotherapy outcome research 
in particular , Weiss and Weisz (1990) examined the results from large meta-analytic 
studies to determine whether methodological factors impacted the magnitude of effect 
sizes. Weiss and Wiesz focused on factors that might compromise internal and external 
validity such as selection bias, subject attrition, random assignment, measurement flaws, 
history, therapist variables, and ecological (clinical vs. analog settings) factors (Campbell 
& Stanley, 1963). Weiss and Wiesz (1990) reported that 
together , these factors accounted for two-thirds as much variance as the 
substantive factors (e.g. , type of therapy , age) in the original meta-
analysis ... [and that] in general , increased experimental rigor was related to 
larger effect sizes; this argues against the hypothesis that methodologically 
weak studies have led to an overestimate of therapy effects. (p . 639) 
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Nonetheless , the quality of each study included in the present analysis will be coded and 
evaluated to examine whether methodological factors impacted treatment outcome . 
Summary 
In summary , depression in children and adolescents is a recognized phenomenon 
that adversely affects the lives of many youth . In light of the prevalence , persistence , and 
negative outcomes associated with depressive disorders in children and adolescents , 
several treatments have been developed ranging from psychosocial interventions to 
pharmacological interventions. Current reviews of the outcome studi es for child and 
adolescent depression have not been adequate for guiding research , policy , and practice 
because many of the reviews are narrative in nature , methodologically flawed , and/or 
present vague or conflicting conclusions . Furthermore , while some of the efforts to 
review and synthesize the body of literature on the treatments for depressed youth have 
answered some questions , there are many more questions left unanswered. If a 
comprehensive, methodologically sound review of the literature on the efficacy of 
psychosocial and pharmacological treatments for childhood depression existed , there 
would be a better understanding of which treatments are effective in ameliorating 
depressive symptomatology in children as well as how outcomes covary with study and 
sample characteristics. Furthermore , a good integrative review would help to guide both 
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intervention efforts and future empirical studies on the treatment of depressive disorders 
in children. 
Purpose and Objectives 
The purpose of this research project was to determine the overall efficacy of 
psychosocial and pharmacological treatments for child and adolescent depression. An 
additional purpose of this inquiry was to examine how certain variables impacted 
treatment outcomes (e.g., age, sex, type of treatment, quality of study). 
The objectives of this study were as follows: 
1. To determine the overall efficacy of psychosocial interventions for child and 
adolescent depression . 
2. To determine the overall efficacy of pharmacological treatments for child and 
adolescent depression. 
3. To determine whether there is differential efficacy for psychosocial and 
pharmacological treatments when the following 11 variables are considered: (a) age, 
(b) sex, (c) referral source, (d) treatment setting, (e) type of treatment, (f) length and 
frequency of treatment, (g) assessment measures, (h) therapist variables, (i) severity of 
illness, (j) comorbidity, and (k) quality of study. 
Given the aforementioned purpose and objectives, the following three research 
questions were addressed in this investigation: 
1. What is the overall efficacy of psychosocial interventions for child and 
adolescent depression? 
2. What is the overall efficacy of pharmacological treatments for child and 
adolescent depression? 
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3. Is there evidence of differential efficacy for psychosocial and pharmacological 
treatments when the following 11 variables are considered: (a) age, (b) sex, (c) referral 
source, (d) treatment setting , (e) type of treatment , (f) length and frequency of treatment , 
(g) assessment measures , (h) therapist variables, (i) severity of illness, (j) comorbidity, 
and (k) quality of study? 
CHAPTER III 
METHODOLOGY 
Population and Sample 
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The population for this investigation included empirical studies on the treatment 
of child and adolescent depression. The overall sample for this investigation included 37 
psychosocial and pharmacological studies targeting child and adolescent depression 
published between 1980-1998. There were 23 psychosocial studies (36 separate 
treatments) and 14 pharmacological trials . Case reports and single-subject designs were 
not included. The articles were located through a comprehensive search strategy 
including an extensive computer search of databases such as PsycLIT , ERIC, and 
Medline . Key words and various combinations were used including : depression , 
depressed , mood , internalizing , child, children, childhood , adolescent , adolescence , 
juvenile , treatment , therapy , psychotherapy , intervention , pharmacotherapy , 
pharmacologic, medication , tricyclic , antidepressant , SSRI, TCA, outcome , and meta-
analysis. Hand searches of the reference lists from the obtained articles were conducted 
in an effort to find additional articles and several authors were contacted to inquire about 
"in press" studies or unpublished manuscripts . Manual searches of a variety of peer-
reviewed journals were completed as well, including the Journal of Consulting and 
Clinical Psychology, the Journal of the American Academy of Child and Adolescent 
Psychiatry , Behavior Therapy, Archives of General Psychiatry, School Psychology 
Review , Behavioral Psychotherapy, the Journal of Clinical Child Psychology, the Journal 
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of Affective Disorders, and the Journal of Child Psychology and Psychiatry. 
Finally, a comprehensive search of unpublished theses and dissertations via 
ProQuest Dissertation Abstracts was completed dating back to 1980. Fifteen potentially 
relevant dissertations were located, of which 10 were ordered. Several of the 
dissertations ordered were not received (i.e., four) due to restrictive lending policies at the 
various institutions. Of the six dissertations received, two were deemed appropriate for 
coding and included in the final sample of studies. 
For a study to be included in the investigation , the effects of a particular treatment 
on child and adolescent depression had to be examined. The following specific criteria 
must have been met as well : (a) the study had to be a within- or between-subjects group 
design ; (b) the sample was targeted for intervention based upon "at risk" status (i.e., 
prevention) , presenting depressive symptomatology , or a depressive diagnosis ; (c) the 
subjects targeted for intervention were between the ages of 5-18; ( d) the treatment was 
psychosocial or pharmacolog ical in nature (e.g., group, individual , family, TCA, SSRI) ; 
and ( e) the study utilized at least one depression outcome measure once the intervention 
was completed . 
Design 
An integrative or meta-analytic design was used during the course of this study , 
whereby the results from related treatment studies can be compared (Glass, 1977). In 
conducting a meta-analysis, the investigator codes the findings from empirical studies and 
converts them into an effect size, a common metric upon which comparisons across the 
various studies can be made. A commonly used effect size is the standardized mean 
difference , that is, the treatment group mean minus control group mean, divided by 
control group or pooled standard deviation (Smith et al., 1980). 
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In terms of what an effect size actually indicates, Cohen (1988) stated that "it is 
convenient to use the phrase ' effect size' to mean ' the degree [d] to which the 
phenomenon is present in the population,' or ' the degree to which the null hypothesis is 
false '" (pp. 9-10) . Effect sizes are typically expressed in standard deviation units (Wolf , 
1986). Thus, if a calculated effect size ( d) is expressed as .50, this is interpreted as one-
half of a standard deviation difference between the means of the groups under study ( e.g., 
treatment versus control groups), indicating that "33% of the combined area covered by 
two normal equal-sized equally varying populations is not overlapped" (Cohen , 1988, p. 
26). Furthermore , Cohen offered guidelines to interpret the magnitude of an effect size. 
According to Cohen (1988), effect sizes between 0.20 and 0.49 are considered "small ," 
effect sizes between 0.50 and 0.79 are considered "moderate ," and effect sizes 0.80 or 
larger have been described as "large." Cohen (1988) suggested that these qualitative 
interpretations are somewhat arbitrary and should be made with caution , keeping in mind 
the particular variables under study. For example, if one is measuring the outcome of a 
blood-pressure reduction treatment wherein the standard deviation is three diastolic 
points, an effect size of 2.0 would be a large effect, but arguably clinically meaningless 
because the effect size is based upon a mean difference of approximately six diastolic 
points . As such, the practical implications of such an effect size are marginal at best. 
Thus, the scaling of the outcome measures must carefully considered before interpreting 
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the magnitude of effect sizes 
In the present study, a meta-analytic design was used because these designs are 
often more efficient and effective than narrative reviews in accurately synthesizing large 
amounts of data from a number of studies (Glass, McGaw, & Smith, 1981). Wolf(1986) 
suggested that some of the common problems associated with narrative reviews can be 
addressed by conducting a meta-analysis, including biased selection of studies, 
differential weighting of studies, misleading interpretations of study findings, and failure 
to examine moderating variables in the questions being addressed. At the same time, it 
has been suggested that the standards of methodological rigor in meta-analyses be just as 
stringent as empirical studies (Wolf, 1986). For example, Glass et al. (1981) grouped 
criticisms of meta-analyses into four domains including: (a) the diversity across studies 
( e.g., sample characteristics, measurement technology, treatment variables) makes 
comparisons inappropriate; (b) the results from poorly designed studies given equal 
weight with well-designed studies skew the results; (c) studies that produce 
nonsignificant findings are rarely published, thus creating a biased sample of studies; and 
( d) studies given too much weight have multiple results. 
The aforementioned criticisms of meta-analytic designs can be addressed in 
various ways. For example, when dealing with the diversity and methodological 
differences across studies, the researcher is best advised to code certain characteristics 
from each study (e.g., treatment type, methodology) and examine whether the variables 
mediate the meta-analytic results (Wolf, 1986). As mentioned previously, analyzing how 
study characteristics covary with outcomes is a major thrust of the study. Thus, a 
systematic coding system was developed and implemented to examine the relationship 
between the 11 broadly construed variables and the treatment outcomes (i.e., ES) . 
As described above, Wilson and Rachman (1983) hypothesized that 
methodologically weaker studies might skew the results from integrative reviews in the 
direction of an overestimation of therapy effects . Thus, in order to account for the 
potential problem of giving poorly designed studies equal weight with well-designed 
studies, the quality of each study was rated on the basis of two criteria: (a) the potential 
threats to internal validity and (b) the overall validity of the study. These criteria were 
analyzed to determine whether there were differential outcomes based on study quality. 
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When dealing with a potentially biased sample of studies, also referred to as the 
"file drawer " problem (Rosenthal, 1979), it has been suggested that a more 
comprehensive search strategy be employed along with broader inclusion criteria (Glass 
et al., 1981 ). As outlined above, a comprehensive search strategy was employed in the 
present study, including a review and solicitation of unpublished manuscripts . Although 
the majority of the studies included in the present analysis were published, a moderate 
amount of data was included from unpublished manuscripts (e.g., Curry & Wells, 1998) 
and dissertations ( e.g ., Hickman, 1994 ). 
With respect to the unequal weighting of studies problem, some authors have 
suggested averaging multiple results from one study to yield perhaps one or two effect 
sizes, thus preventing studies with multiple results from having undue influence on the 
overall estimate of the effect size across studies (Smith et al., 1980). To address this 
issue in the present investigation, a maximum of two effect sizes per treatment modality 
were calculated to prevent unequal weighting of the effects from a particular study with 
the potential for multiple effect size calculations. 
Instrumentation and Analysis 
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A comprehensive coding sheet was developed so that each of the treatment 
outcome studies was evaluated based on 11 broadly construed variables including: (a) 
age, (b) sex, (c) referral source, (d) treatment setting, (e) type of treatment, (t) length and 
frequency of treatment, (g) assessment measures, (h) therapist variablesm (i) severity of 
illness, (j) comorbidity, and (k) quality of study. The quality of each study was rated 
based on: (a) potential threats to internal validity and (b) the overall validity of the study. 
Seven potential threats to internal validity were evaluated on a scale of O to 3 (0 = not a 
plausible threat; 1 = minor threat; 2 = plausible threat ; 3 = by itself could explain the 
findings) . The potential threats included: maturation, history, testing, instrumentation, 
regression, selection bias, and experimental mortality. These threats to internal validity 
and the associated effects upon treatment outcomes have been described extensively in 
the literature (e.g., Borg & Gall, 1989; Campbell & Stanley, 1963). The overall validity 
of study was assessed based on several factors including the aforementioned threats to 
internal validity, sample size, selection procedures, methodological rigor, and 
measurement technology. A 5-point Likert scale (5 = excellent; 4 = good; 3 = fair; 2 = 
inferior; 1 = unacceptable) was used to evaluate each study. 
Each study was double-coded by the primary researcher and a second Ph.D. 
candidate in psychology with extensive experience in coding studies for meta-analytic 
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designs. The second coder was trained in the specific procedures outlined in this study, 
and interrater reliability coefficients were calculated for each variable coded. Two 
formulas were used to calculate the interrater agreement. First, interrater reliability was 
calculated by dividing the total number of congruent observations (CO) by the total 
number of observations (TO) and multiplied by 100. Second, Cohen 's Kappa (Cohen , 
1960) was calculated for each variable to compensate for the limitations in the first 
formula since the procedure is used to determine agreement beyond chance levels. After 
calculating reliability data, disagreements in the coding of certain variables were 
reconciled through consultation and clarification among the coders. A copy of the coding 
sheet is included in the Appendix. 
The results and variables from the various treatment studies were analyzed by 
computing a number of effect sizes. Effect sizes were calculated with the assistance of 
the DST AT computer software program (Johnson, 1989) whereby the outcome data (i .e., 
means , standard deviations , sample sizes) were entered . In cases where the means and 
standard deviations were not provided, effect sizes were computed from other data 
reported in the studies (e.g., f-ratios or !-statistics). Furthermore , in a large number of 
pharmacologic studies means , standard deviations, f-ratios , or !-statistics were not 
reported. Instead, the percentage of improvement in the treatment and placebo-control 
groups was reported . Treatment response in these studies was determined by whether the 
subjects met criteria for "improvement " (i.e., change observed on particular measures). 
However, the criteria for improvement and the measures utilized to determine change 
varied across the studies. Nonetheless, effect size estimates were calculated by 
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transforming the difference in proportions (percent improved) between the experimental 
and placebo-control group subjects. This procedure (probit transformation) has been used 
in a number of meta-analyses ( e.g., Clum, Clum, & Surls, 1993; Miller, 1977) and is 
described elsewhere (see Smith et al., 1980). 
Although this procedure is far from ideal in calculating ES, it is more effective 
and accurate than simply excluding the study from the analysis. One of the primary 
limitations of this procedure is the inevitable loss of information that takes place after the 
outcome data are transformed multiple times into an effect size. Nonetheless, it addresses 
a criticism (Anderson, 1995) of a previous meta-analysis (Hazell et al., 1995) on the 
efficacy of using antidepressant medications in children and adolescents whereby effect 
sizes were calculated from only 6 of the 12 studies due to the limited data contained in 
the articles . For studies that did not report any data suitable for conversion to effect sizes, 
but were important to include in the final analysis to increase comprehensiveness (and to 
reduce selection bias), an effect size estimate of zero was entered. Assigning an effect 
size of zero is a conservative procedure designed to prevent an inflated overall effect size 
estimate, when including important, albeit incomplete information from particular studies 
(Rosenthal, 1984 ). In the present study, an effect size of zero was entered only when the 
data could not be converted to an effect size and the authors reported nonsignificant 
differences between the active and placebo conditions. An effect size of zero was entered 
for three of the pharmacological studies that reported nonsignificant differences between 
the active versus the placebo conditions and the data in the articles were insufficient to 
compute effect sizes. 
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For between-subjects group designs, the traditional meta-analytic formula, first 
proposed by Glass (1977), was utilized whereby unweighted effect sizes are calculated by 
subtracting the control group mean from the treatment group mean, divided by the control 
group (Glass, 1977) or the pooled standard deviation (standard deviation of treatment and 
control or Cohen's .d; Cohen, 1988). Because the size of the denominator (i.e., standard 
deviation) in this formula can have a serious impact on the magnitude of effect, a 
concerted effort was made to obtain the best estimate of the variance of an untreated 
sample . Thus, in this study, the "pooled" standard deviation included the variance of the 
treatment group before treatment in addition to the variance of the no-treatment or wait-
list control group. This procedure is often helpful in obtaining a more accurate estimate 
of the variance of an untreated group (Karl White, personal communication, February 19, 
1998). 
Despite the fact that a large number of meta-analytic reviews have used 
unweighted effect size calculations ( e.g., Casey & Berman, 1985; Smith et al., 1980), 
there is a recent trend in the literature to use a weighted effect size procedure ( e.g., 
DuPaul & Eckert , 1997; Weisz, Weiss, et al., 1995). The unweighted least squares model 
(ULS) relies on several statistical assumptions, most notably the assumption of 
homogeneity of variance. That is, the means and standard deviations (i.e., variance) are 
equivalent across groups and observations. This assumption is closely related to 
distribution and sample size factors. In meta-analytic studies, individual observations are 
the ES. Thus, when aggregating a number of effect sizes (i.e., averaging effect sizes 
across studies), the assumption of homogeneity of variance is often violated in meta-
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analytic reviews because many of the studies often have substantial differences in sample 
sizes. The weighted least squares (WLS) general linear model has been described as a 
more reliable way to compute effect size estimates since the procedure corrects for biased 
estimates derived from smaller samples (Hedges & Olkin, 1985). In brief, this procedure 
corrects for smaller samples by weighting the effect sizes by the inverse of its variance . 
However , the WLS method has also met with criticism because comparisons 
between previous ULS meta-analytic studies and more recent WLS studies are 
problematic since it would be difficult to determine whether the differences were related 
to the data or associated artifactually to the analytical procedures . In the meta-analysis 
conducted by Weisz, Weiss, et al. (1995), they calculated effect size estimates using both 
the ULS and WLS methods. Based on the six depression treatment studies included in 
the analysis , the ULS effect size estimate was 0.67, whereas the WLS effect size estimate 
was 0.64. Thus, practically speaking, the WLS method had little impact upon the average 
effect size for depression treatment studies . In light of these data, coupled with the fact 
that the DST AT program is based on the ULS model , the unweighted least squares model 
was utilized in this study to facilitate comparisons across ULS meta-analyses . 
For within-subjects group designs, unweighted effect sizes were calculated as 
well. However , in these studies, the effect size was interpreted as the magnitude of 
change observed in the experimental group from the pretreatment to posttreatment phases 
(i.e. , intrasubject variance) . It was hypothesized that these effect sizes would be larger in 
general , due to the fact that the magnitude of these effect sizes were not mediated by the 
measurement of change due to the mere passage of time (i.e., "treatment" effect for 
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control group subjects) . As such, comparisons of within- and between-group effect sizes 
were inappropriate. However , pre-/post-effect sizes were calculated for the between-
group designs to facilitate a useful comparison of treatments across the two designs. 
A variety of procedures were used to extract and subsequently analyze the data 
from early-onset depression treatment studies. Comparisons of the main effects, potential 
interactions , and other specified variables were conducted. Further, to gain an idea of the 
robustness of the findings , two additional interpretive aids were used. In addition to 
Cohen ' s (1988) guidelines, the magnitude of the overall mean difference effect sizes were 
interpreted based on 95% confidence intervals (Cl) and a Fail Safe N procedure was used. 
The Fail Safe N procedure , first used by Rosenthal (1979) and described by Cooper 
( 1979), generally denotes the number of studies with null effects that would be needed to 
reverse the conclusion that a statistically significant relationship exists based on the 
criterion values , usually 12 = .05 or .01 (Wolf, 1986). Orwin (1983) adapted this 
procedure for meta-analytic designs whereby an effect size criterion value is substituted 
for the probability values. Orwin suggested that Cohen's (1988) guidelines be used as the 
criterion values (i.e., effect sizes between 0.20 and 0.49 = small; effect sizes between 0.50 
and 0.79 = moderate ; effect sizes of 0.80 or greater= large). The Fail Safe N for meta-
analytic designs is interpreted as the number of studies with a particular criterion value 
( e.g., effect sizes = 0.20) that are required to bring down the average effect size to that 
given criterion value (i.e., small effect). In essence, the Fail Safe N procedure helps to 
account for one of the criticisms (i.e., selection bias) of meta-analyses in that it provides 
an index of how many studies with "small" effects (unpublished or not included) that 
would be needed to diminish the overall effect size to a "small" effect. 
Summary 
In summary, a comprehensive sample of studies on the psychosocial and 
pharmacological treatment of early-onset depression were located through an extensive 
literature search. Articles that met the inclusionary criteria were subsequently analyzed. 
The outcome data from 3 7 outcome studies were extracted and converted into effect 
sizes. Comparisons of main effects, potential interactions, and other specified variables 
were conducted . Finally, the data were discussed within the context of a number of 
interpretive aids often used in meta-analytic designs. 
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CHAPTER IV 
RESULTS 
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The presentation ofresults is divided into the following four sections: (a) 
descriptive statistics , (b) intercoder agreement ratings, ( c) main effects, and ( d) analysis of 
study variables. 
Descriptive Statistics 
Psychosocial Studies 
Of the 23 psychosocial studies included in the analysis, 14 (61%) were between-
subject group studies with wait-list , placebo , or no-treatment control groups. The 
remaining nine (39%) psychosocial studies utilized a within-subject (pre/post) group 
design . The psychosocial studies were published or conducted between 1980 and 1998, 
with the vast majority of studies published after 1990 (i.e., 87%). There were 36 active 
treatments across all 23 psychosocial studies and two attention-placebo conditions . The 
modal treatment regimen was cognitive-behavioral group therapy (n = 11 ), followed by 
nondirective , supportive individual therapy (n = 3), social skills group therapy (n = 3), 
cognitive-behavioral individual therapy (n = 4), and relaxation group therapy (n = 2). The 
remaining treatments included nondirective supportive group therapy, residential 
treatment , behavioral group therapy, aerobic exercise, individual relaxation therapy, role 
playing , family therapy, interpersonal therapy , and various combinations (e.g., group CBT 
plus parent group or group CBT plus family therapy). There were three prevention 
studies, 11 studies in which the subjects were targeted based on depressive 
symptomatology, and nine studies where the subjects were included based on a 
depressive diagnosis (i.e., major depressive disorder and/or dysthymic disorder). 
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In the between-subject group studies, there were 985 subjects between the ages of 
7 and 18 years old. The number of subjects in each of the controlled studies ranged from 
7 to 152 (median= 57.5). There were five (35%) controlled studies in which the average 
age of the subjects was above 13 years old, whereas nine (65%) studies included subjects 
with a mean age of below 13 years old. In the within-subject group designs, there were 
391 subjects between the ages of 5 and 18 years old. The number of subjects in each of 
the pre-/poststudies ranged from 8 to 107 (median = 46). Of the nine pre-/poststudies, six 
(66%) included subjects with an average age above 13 years old, whereas three (33%) 
studies included subjects with a mean age below 13 years old. The average percentage of 
female subjects across all 23 studies was approximately 56%. However, only 3 of the 23 
studies (13%) reported separate findings based on sex. 
The number of therapy sessions in the controlled trials ranged from 8 to 27 
(median= 10.5) and the number of weeks for each treatment ranged from 2 to 12 weeks 
(median= 8). The number of sessions in the pre-/poststudies ranged from 5 to 36 
(median = 11) and the number of weeks for each treatment ranged from 4 to 24 weeks 
(median= 12). Of the 14 controlled studies, 9 (64%) included follow-up data, ranging 
from 1 month to 1 year posttreatment (median= 6.5 weeks). Among the nine pre-/ 
posttrials, five (55%) included follow-up data, ranging from 1 month to 1 year 
posttreatment (median= 4 months). See Table 1 for a descriptive summary. 
Table 1 
Frequency and Percentage of Study Characteristics 
Characteristics 
Total number of studies reviewed 
Number excluded 
Reasons for exclusion 
Single-subject or case report 
Sample not at risk or depressed 
No depression outcome measure 
Insufficient data to compute ES 
Total number of studies included 
Type of study 
Psychosocial treatment 
Between-subject ( controlled) 
Within-subject (pre/post) 
Pharmacological treatment 
Between-subject ( controlled) 
Within-subject (pre/post) 
Year of publication (psychosocial) 
1980-1984 
1985-1989 
1990-1994 
1995-1998 
Year of publication (pharmacological) 
1980-1984 
1985-1989 
1990-1994 
1995-1998 
Source of study 
Published study 
Dissertation or thesis 
Unpublished manuscript 
Follow-up assessment (psychosocial) 
1-9 weeks 
9-16 weeks 
>16 weeks 
Frequency 
55 
18 
8 
3 
2 
5 
37 
23 
14/23 
9/23 
14 
14/14 
0/14 
1 
2 
8 
12 
3 
2 
6 
3 
34 
2 
1 
14/23 
5/14 
1/14 
8/14 
Percentage 
100.0 
32.7 
44.5 
16.7 
11.1 
27.7 
67.3 
62.2 
60.9 
39.1 
37.8 
100.0 
0.0 
4.3 
8.7 
34.8 
52.2 
21.4 
14.3 
42.9 
21.4 
91.9 
5.4 
27.7 
60.8 
35.7 
7.1 
57.2 
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Pharmacological Studies 
All 14 pharmacological studies included in the analysis were controlled clinical 
trials with active medication and placebo conditions , with the exception of one study in 
which an inactive placebo pill was combined with psychotherapy (Mandoki et al., 1997). 
All 14 studies included subjects based on a diagnosis of major depressive disorder based 
on DSM criteria (AP A, 1980, 1987, 1994) and information solicited from self-report 
measures , interviews, and observations. The pharmacological trials were published or 
conducted between 1981 and 1997 and 64% of studies were published after 1990. There 
were 441 subjects between the ages of 6 and 19 years old. The number of subjects in each 
of the pharmacological trials ranged from 6 to 96 (median= 30). There were six (43%) 
studies in which the subjects were 12 years of age or younger, six ( 4 3 % ) studies in which 
the subjects were 13 years of age or older , and two (14%) studies in which there were 
children and adolescents ranging from 7 to 17 years old (Emslie et al., 1997) and 8 to 17 
years old (Mandoki et al., 1997). The average percentage of female subjects across all 
pharmacological studies was approximately 42%. However , none of the studies reported 
separate findings based on sex. 
The types of medications used in the pharmacological trials included imipramine 
(Tofranil; n = 4), amitriptyline (Elavil; n = 3), desipramine (Norpramin ; n = 2), 
nortriptyline (Pamelor; n = 2), fluoxetine (Prozac; n = 2), and venlafaxine (Effexor; 
n = 1). The number of weeks for each treatment ranged from 4 to 8 weeks (median= 6). 
The outcome data in the pharmacological trials were reported at the end of the acute 
phase of pharmacotherapy (i.e., posttreatment) . Follow-up data were not included in the 
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original articles. See Table 1 for a descriptive summary. 
lntercoder Agreement 
As described in Chapter Ill, 25 psychosocial studies were double-coded by the 
primary researcher and a second Ph.D. candidate in psychology. Although two of the 
studies rated were not included in the final sample, the intercoder agreement data from 
these studies were retained to increase the chances of obtaining valid reliability estimates 
for the entire sample of studies. The pharmacological articles were not double-rated due 
to the limited number of variables, relative to the psychosocial studies, that were deemed 
suitable for coding. Two formulas were used to calculate the interrater agreement. First, 
interrater agreement percentages were calculated by dividing the total number of CO by 
the total number of observations TO and multiplied times 100. Second, Cohen's Kappa 
(Cohen, 1960) was calculated for each variable to compensate for the limitations in the 
first formula. Disagreements in the coding of any variables were reconciled through 
consultation and clarification among the coders. Interrater agreement rates ranged from 
88-100% with an average agreement of 95.3%. Kappa coefficients ranged from 0.76 to 
1.00, with an average Kappa reliability coefficient of .91. See Table 2 for a summary of 
intercoder agreement ratings on key study variables. 
Main Effects 
Psychosocial Studies 
As mentioned previously, one of the primary objects of the current investigation 
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Table 2 
Intercoder Agreement and Cohen's Kappa of Study Variables 
Study variable Intercoder agreement % Cohen's Kappa 
Average age of subjects 100 1.00 
Percent female 96 0.92 
Referral source 92 0.84 
Treatment setting 92 0.84 
Type of treatment 100 1.00 
Treatment variables 
Frequency (sessions) 96 0.92 
Length (weeks) 100 1.00 
Assessment measures 96 0.92 
Therapist variables 92 0.84 
Severity of illness 100 1.00 
Comorbidity 92 0.84 
Quality of study 88 0.76 
was to determine the overall efficacy of psychosocial interventions for child and 
adolescent depression. Tables 3 through 6 provide a summary of key information 
regarding study main effects. Based on a review of the 14 controlled psychosocial studies 
(21 treatments) included in the analysis, the overall mean difference effect size at 
posttreatment was 0.74 (range= 0.03 - 1.84; 95% CI 0.49 - 1.01), indicating that the 
average child who received treatment for depression was better off than approximately 
77% of the children who did not. Of the eight controlled psychosocial studies that 
reported follow-up data, the mean effect size was 0.64 (range= 0.08 - 1.55; 95% CI 0.32 
- 0.95), indicating that the average treated child was better off at follow-up (median= 6.5 
weeks) than approximately 74% of control group subjects. Based on the Fail Safe N 
formula with the criterion level set at 0.20 (i.e., small effect), it would take approximately 
Table 3 
Overall Mean Effect Sizes at Posttreatment 
Type of study 
Controlled psychosocial 
Intrasubject treatment 
Intrasubject control 
Pre-/postpsychosocial 
Pharmacological 
14 (21 treatments) 
9 ( 15 treatments) 
13 
Mean ES 
.74 
(1.23) 
(0.37) 
1.14 
.19 
95%CI 
0.49 - 1.01 
0.75 - 1.52 
-0.08 - 0.45 
Note. Parenthetical ES values reflect amount of change on the dependent measures that 
was observed in controlled studies using intrasubject (pre/post) variance estimates. 
Table 4 
Overall Mean Effect Sizes at Follow-up 
Type of study N Mean ES 95% CI 
Controlled psychosocial 8 ( 12 treatments) .64 0.32 - 0.95 
Pre-/postpsychosocial 5 (8 treatments) 1.26 0.99 - 1.52 
Pharmacological 13 
56 studies, all with effect sizes of 0.20, to bring down the overall posttreatment mean 
effect size to 0.20 
In regards to the nine pre-/postpsychosocial studies (15 treatments), the overall 
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mean effect size at posttreatment was 1.14 (range= 0.23 - 2.30; 95% CI 0.75 - 1.52). For 
the five studies that reported follow-up data, the mean effect size at follow-up (median = 
36 weeks) was 1.26 (range 0.95 - 1.94; 95% CI 0.99 - 1.52; see Tables 3 and 4). Based 
on the Fail Safe N formula with the criterion level set at 0.20 (i.e., small effect), it would 
take approximately 70 studies, all with effect sizes of 0.20, to bring down the overall 
posttreatment mean effect size to 0.20. 
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Table 5 
Effect Sizes at Posttreatment and Follow-Up for Controlled Psychosocial Studies 
Authors Sample Treatment Post ES .E-ES 
Brown et al. ( 1992) 7 female adolescents Aer Exer 0.18 
( ages 13-16) with 
depressive symptoms 
Butler et al. (1980) 56 children CBT-G 0.09 
(ages 9-12) with RP-G 0.29 
depressive symtoms Attn-Plac -1.15" 
Clarke et al. ( 1995) 120 adolescents CBT-G 0.31 0.10 
(ages 13-17) with 
depressive symptoms 
Hickman (1994) 9 children (ages 8-11) with SS-G 0.73 0.72 
depressive symptoms 
Jaycox et al. (1994); 143 "at-risk" children CBT-G 0.31 0.31 
Gillham et al. ( 1995) (ages 10-13) with 
depressive symptoms 
Kahn et al. ( 1990) 68 children (ages 10-14) CBT-G 1.84 1.25 
with depressive symptoms Rix-G 1.30 0.80 
CBT-I 1.25 0.68 
Lewinsohn et al. (1990) 59 adolescents ( ages 14-18) CBT-G I.I I 
with MOD or Dysthymia CBT-G + P 1.45 
Lewinsohn et al. ( 1996) 96 adolescents ( ages 14-18) CBT-G and 
with MDD or Dysthymia CBT-G+P 0.39 
0.26 
Liddle & Spence ( 1990) 31 children (ages 7-11) CBT-G 0.52 
-0.33 
with depressive symptoms Attn-Plac -0.51" 
Rawson & Tabb (1993) 127 children (ages 8-12) Residential 0.40 
with depressive symptoms 
0.20 
Reivich ( 1996) 152 "at-risk" children CBT-G 0.03 0.08 
(ages 12- 14) with NST-G 0.18 
depressive symptoms 
1.27 
Reynolds & Coats 30 adolescents (ages 14-18) CBT-G 1.48 1.55 
(1986) with depressive symptoms Rix-G 1.57 
Stark et al. (1987) 29 children (ages 9-12) CBT-G 0.93 
with depressive symptoms BPS-G 0.68 
0.51 
Weisz et al. ( 1997) 48 children (ages 8-12) CBT-G 0.54 
with depressive symptoms 
Note . See Table 6 notes for abbreviations . 
"Attention-Placebo group effect sizes not included in mean effect size calculations because they were not active 
treatment conditions. 
bFollow-up data reported but not suitable for conversion to effect sizes. 
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Table 6 
Effect Sizes at Posttreatment and Follow-Up for Each Pre- and Postpsychosocial Study 
Authors Sample Treatment Post ES F-ES 
Brent et al. (1997) 107 adolescents CBT-1 2.30 
(ages 13-18) with MOD SBFT 1.61 
NST-1 2.04 
Curry & Wells (1998) I I adolescents CBT-G + F 1.41 
(ages 14-17) with MOD or 
Dysthymia and comorbid 
substance abuse 
Fine et al. (1991) 66 adolescents SS-G 0.23 1.12 
(ages 13-17) NST-G 0.76 1.16 
with MDD or Dysthymia 
King et al. ( 1990) 46 "at-risk " children SS-G 0.96 
(ages 5-11) Consult 0.25 
Mufson et al. (1994) ; 14 adolescents IPT-1 2 .02 1.94 
Mufson et al. (1996) (ages 13-16) with MOD 
Reed (1994) 8 male adolescents SS-G 1.45 0.95 
(ages 14-19) with 
MDD or Dysthmia 
Vostanis et al. ( 1996) 56 children and adolescent s CBT-I 1.30 1.28 
(ages 8-17) with NFI-1 0.89 0.95 
MDD or Dysthymia 
Wagner et al. (1993) 30 female adolescents NST-1 0.24 
(ages 9-15) with 
depressive symptoms 
Wood et al. (1996) 53 children and adolescents CBT-1 1.33 1.43 
(ages 11-17) with Rix-I 0.30 1.27 
MDDorDD 
Note . Aer Exer=Aerobic Exercise; Alt-Tx=Altemative Treatment; Attn-Plac=Attention-Placebo Group ; 
CBT-G=Cognitive-Behavioral Therapy-Group; CBT-J=Cognitive-Behavioral Therapy-Individual ; 
Consult=Consultation; F=Family Therapy; IPT-I=Interpersonal Psychotherapy-Individual; NFI-I=Non-
focused Intervention-Individual; NST-I=Non-Directive Supportive Therapy-Individual; P=Parent; PS-
G=Problem-Solving Group; PsyEd-G=Psychoeducational Group; Rlx-I=Individual Relaxation Therapy ; 
Rlx-G=Group Relaxation Therapy ; RP-G=Role-Play Group; SS-G=Social Skills Group; SBFT=Structured 
Behavior Family Therapy. 
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However , because these effect sizes were calculated based on intrasubject 
variance , the mean effect size reflects an overall decrease in the amount of depressive 
sequelae as measured by the various outcome instruments across all studies. Without 
control group comparisons , it was virtually impossible to estimate how much of the 
treatment effect, as determined by the dependent measures , was attributable to the 
treatment as opposed to extraneous factors such as the mere passage of time. Therefore , 
in order to facilitate a useful comparison of the mean effect sizes of the between- and 
within-subject group designs, pre-/post-effect sizes were also calculated for the controlled 
studies. The overall mean effect size for controlled studies using intrasubject variance 
estimates was 1.23 (range= 0.30 - 2.27; 95% CI .90 - 1.55), which was comparable with 
the average effect size for the pre-/poststudies (i.e., ES = 1.14). To gather an 
understanding of the amount of change that occurred without treatment , pre-/post-effect 
sizes were calculated for control group subjects only. The pre-/post-effect size 
calculations for control group subjects yielded a mean effect size of 0.3 7 averaged across 
the 14 studies . These data approximate the amount of change between the pretreatment 
and posttreatment phases that could not be explained by or attributed to the therapeutic 
interventions themselves (see Table 3). 
Pharmacological Studies 
Of the 14 pharmacological trials that compared active versus placebo response 
rates, effect sizes were entered for all but one study (i.e., Mandoki et al., 1997), due to the 
fact that the active medication was compared to a placebo plus psychotherapy condition, 
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thus introducing a confound to the comparison. Moreover, the authors reported that 
almost 66% of the subjects in both conditions responded positively to the treatment. 
Nonetheless, the overall mean effect size of the pharmacological studies at posttreatment 
was 0.19 (range -0.88 - 1.19; 95% CI -0.08 - 0.45), suggesting that the average subject 
who was administered the active medication moved to the 58th percentile in the 
distribution of subjects who took the placebo. Follow-up data were not reported in the 
pharmacological studies (see Tables 3, 4, and 7). Because the magnitude of the mean 
effect size for pharmacological studies was below Cohen's suggested guidelines for a 
"small effect," the Fail Safe N formula was not calculated. 
Analysis of Study Variables 
As previously noted, no published studies were located that addressed specifically, 
the potential interaction between age and the treatment of early-onset depression . To 
complicate matters, differentiating between "child" and "adolescent" samples can be 
erroneous and potentially misleading. However, in order to facilitate a useful analysis of 
the potential interaction of age and treatment outcome, a false dichotomy was created 
whereby child studies were defined as having a mean age of 12 or younger and adolescent 
studies were characterized by a sample with a mean age of 13 or older. Although the 
most appropriate differentiation between child and adolescent samples remains the 
subject of much debate, the aforementioned definitions appear most frequently in the 
published literature (e.g., Emslie et al., 1997; Weisz, Weiss, et al., 1995). Further, the 
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Table 7 
Effect Sizes Comparing Active Versus Placeboy Positive Response Rates for Controlled 
Pharmacological Studies 
Authors Sample 
Boulos et al. ( 1991) 30 adolescents (ages 15-19) 
with MDD 
Emslie et al. (1997) 96 children and adolescents 
(ages 7-17) with MDD 
Geller et al. (1990) 31 adolescents (ages 12-17) 
with MDD 
Geller et al. ( 1992) 50 children (ages 6-12) 
with MDD 
Hughes et al. ( 1990) 27 children (ages 6-12) 
with MDD and Comorbid 
Anxiety or CD/ODD 
Kashani et al. (1984) 9 children (ages 9-12) 
with MDD 
Kramer & Feiguine (1981) 20 adolescents (ages 13-17) 
with MDD 
Kutcher et al. (1994) 60 adolescents (ages 15-19) 
with MDD 
Kye et al. ( 1996) 22 adolescents (ages 12-17) 
with MDD 
Mandoki et al. ( 1997) 33 children and adolescents 
(ages 8-17) with MDD 
Petti & Law (1982) 6 children (ages 6-12) 
with MDD 
Preskom et al. (1987) 22 children (ages 6-12) 
with MDD 
Puig-Antich et al. (1987) 38 children (ages 6-12) 
with MDD 
Simeon et al. (1990) 30 adolescents (ages 13-18) 
Treatment 
Desipramine 
Fluoxetine 
Nortriptylin e 
SMDES-CDRS 
N ortripty line 
SMDES-CDRS 
Imipramine 
MDD+Anx 
MDD+ 
CDD/ODD 
Am itripty I ine 
Amitriptyline 
Desipramine 
Amitriptyline 
SMDES-HAM-D 
Venlafaxine 
Imipramine 
Imipramine 
% change CDRS 
% change CD! 
Imipramine 
Fluoxetine 
ES 
0.44 
0.59 
-0.61 
(0.49) 
0.46 
(1.12) 
0.07 
(1.02) 
(-0.88) 
o.oo· 
o.oo· 
0.34 
1.19 
(0.53) 
0.12 
0.14 
(0.21) 
(0.06) 
-0.31 
o.oo· 
Note. Anx=Anxiety; CDE=Children's Depression Inventory; CDRS=Child Depression Rating Scale; 
HAM-D=Hamilton Rating Scale for Depression; MDD=Major Depressive Disorder; ODD=Oppositional 
Defiant Disorder; SMDES=Standard Mean Difference Effect Size. 
•zero entered due to insufficient data to compute ES estimates and nonsignificant differences reported for 
active versus placeboy comparisons. Parenthetical ES values reflect separate calculations based on data 
from dependent measures contained in the articles or outcomes based on interactional variables . 
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age-by-treatment outcome interactions were discussed within the context of each type of 
study. That is, separate findings were reported for controlled psychosocial, pre-/ 
postpsychosocial, and pharmacological studies. 
In the nine controlled psychosocial studies where the average age of the subjects 
was 12 or younger, the mean effect size was 0.65 (95% CI 0.34 - 0.95). In contrast, the 
five controlled adolescent studies yielded an average effect size of 0.93 (95% CI 0.36 -
1.49). In regards to pre-/postpsychosocial studies, the mean effect size for child samples 
was 0. 73 (95% CI 0.14 - 1.30), whereas the mean effect size for the six adolescent studies 
was 1.35 (95% CI 0.83 - 1.85). 
Regarding to the pharmacological trials, there were six studies in which the 
average age was 12 or younger, seven studies in which the average age was 13 or older, 
and one study in which the ages ranged from 7 to 17 years (Emslie et al., 1997). 
However, the authors stratified the sample by age (:S 12 and 2:: 13) and reported no 
differences in outcome based on age. Therefore, age-by-treatment outcome data from this 
study were included in the child and adolescent analyses. For child pharmacotherapy 
trials, the mean effect size was 0.15 (95% CI -0.12 - 0.42), whereas adolescent 
pharmacological studies yielded an average effect size of 0.28 (95% CI -0.24 - 0. 79). See 
Table 8 for a summary of data on age and mean effect size. 
As described above, the interaction between sex and therapy outcome has been 
investigated. However, despite some interesting trends, the relationship between sex and 
Table 8 
Mean Effect Sizes Based on Average Age of Sample 
Type of dtudy 
Controlled psychosocial 
Child studies 
Adolescent studies 
Pre-/postpsychosocial 
Child studies 
Adolescent studies 
Pharmacological 
9 
5 
3 
6 
Mean ES 
0.65 
0.93 
0.73 
1.35 
95%CI 
0.34 - 0.95 
0.36 - 1.49 
0.14 - 1.30 
0.83 - 1.85 
Child studies 7 0.15 -0.12 - 0.42 
Adolescent studies (8) 0.28 -0.24 - 0.79 
Note. Parenthetical N refers to the data from the Emslie at al. ( 1997) study which was 
included in both classifications. 
outcome is unclear, especially in relation to the treatment of early-onset depression. 
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Nonetheless, given the epidemiological data which indicate that the female-to-male ratios 
for depressive illness begin to approximate the base rates for adult depressive disorders 
(i.e., approximately 2: 1) during middle to late adolescence, it would be important to know 
whether there are trends of differential efficacy based on sex. 
Exploratory correlational analyses revealed little in terms of an interaction 
between sex and psychosocial depression treatment outcome. For example, the Pearson 
product-moment correlation between the percentage of female subjects and the mean 
effect size in controlled studies was 0.16 fu = .48) and explained approximately 2.5% of 
the variance. Furthermore, the correlational data from pharmacological trials were even 
more dismal, which could be attributed, in part, to the truncated range of female 
percentages observed across medication studies. 
However, when the data from psychosocial studies were analyzed by calculating 
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effect sizes using different percentages of female subjects as criteria, there were some 
noteworthy findings. For example, when the percentage of female subjects in controlled 
studies was 60 or greater (i.e., the majority), the mean effect size was 0.90, as compared 
to an effect size of 0.63 when the percentage of female subjects was below 60. Similarly, 
in pre-/poststudies, when the percentage of female subjects was 60 or greater, the average 
effect size was 1.20, whereas the mean effect size was 1.04 when the percentage of 
female subjects dropped below 60. See Table 9 for a summary of data on sex and effect 
size. 
Referral Source 
As mentioned previously, the interaction between referral source and treatment 
efficacy has important implications for clinicians and researchers. Based on the 36 
psychosocial treatment regimens (23 studies) included in this review, there were 15 
clinically referred and 21 nonreferred groups . Most of the clinically referred samples 
occurred in the context of within-subject designs (i.e., 12), whereas there was a 
predominance of nonreferred samples in the controlled trials (i.e., 18). In regard to 
pharmacological interventions, all of the samples were clinically referred children with a 
diagnosis of major depressive disorder. Thus, the interaction between referral source and 
pharmacotherapy was not examined . 
The mean effect size for clinically referred subjects in controlled trials was 0.44, 
whereas the average effect size for nonreferred youngsters in controlled trials was 0.79. 
Comparatively, the mean effect size was 1.20 for clinically referred children in pre-/ 
poststudies. In the case of nonreferred children and adolescents in within-subject designs, 
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Table 9 
Interaction Between Effect and Sex in Psychosocial Studies 
Type of study N Mean ES 
Controlled studies 
::: 60% female 8 0.90 
< 60% female 6 0.63 
Pre-/poststudies 
::: 60% female 5 1.20 
< 60% female 4 1.04 
the average effect size was 0.89. See Table 10 for a summary of findings . 
Treatment Setting 
In the present investigation , 36 psychosocial treatments were delivered in school 
settings , outpatient clinics, and inpatient hospitals . The school (n = 15; 71 % ) was the 
modal setting in controlled psychosocial trials, whereas the outpatient clinic (n = 12; 
80%) was the predominant setting in pre-/poststudies . In terms of pharmacological 
studies , there were six inpatient trials , seven outpatient trials , and one study in which the 
treatment setting could not be accurately determined but included a number of outpatients 
(i.e., Simeon et al., 1990). 
The average effect size for controlled studies conducted in schools was 0.75. 
Controlled psychosocial treatments conducted in outpatient settings (n = 4) yielded a 
mean ES of 0.92. In terms of the pre-/poststudies , outpatient treatments produced an 
average ES of 1.22, whereas the two school-based interventions yielded a mean ES of 
0.61. Medication trials conducted in outpatient settings ( effect sizes = 0.26) produced a 
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Table 10 
Interaction Between Effect Size and Referral Source in Psychosocial Studies 
Type of study N (treatments) Mean ES 95%CI 
Controlled studies 
Referred 3 0.44 -0.25 - 1.12 
N onreferred 18 0.79 0.50 - 1.08 
Pre-/poststudies 
Referred 12 1.20 0.74 - 1.66 
N onreferred 3 0.89 -0.61 - 2.38 
higher mean effect size than inpatient regimens (effect sizes= -0.06). See Table 11 for a 
summary of data on treatment setting and effect sizes. 
Type of Treatment 
As reported above, one of the major objectives of this investigation was to 
examine the differential effectiveness of a variety of treatment modalities in ameliorating 
depressive sequelae in children and adolescents. As presented in Table 12, the modal 
psychosocial intervention for depressed youth was cognitive-behavioral group therapy 
(n = 11; 31%), which yielded an average effect size of0.69. Other common interventions 
included nondirective supportive individual therapy (n = 3; 8%; Mean effect size= 1.05), 
cognitive-behavioral individual therapy (n = 3; 8%; Mean effect size= 1.64), social skills 
group therapy (n = 3; 8%; Mean effect size= 0.88), and relaxation group therapy (n = 2; 
6%; Mean effect size= 1.43). Further, there were two attention-placebo conditions that 
yielded an average effect size of -0.83. See Tables 12 and 13 for a summary of data on 
treatment type and effect size. 
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Table 11 
Mean Effect (ES) Based on Treatment Setting 
Type of study N (treatments) Mean ES 95%CI 
Controlled psychosocial 
School 15 0.75 0.42 - 1.08 
Outpatient 4 0.92 0.18 - 1.62 
Inpatient 2 0.29 -1.10-1.68 
Pre-/pospsychosocial 
School 2 0.61 -3.90 - 5.11 
Outpatient 13 1.22 0.80 - 1.64 
Pharmacological 
Outpatient 8 0.26 -0.20 - 0.73 
Inpatient 6 -0.06 -0.13 - 0.12 
Table 12 
Mean Effect Size by Treatment Modality in Controlled Psychosocial Studies 
Treatment N (treatments) Mean ES 
Aerobic exercise 1 0.18 
Attention placebo 2 -0.83 
Behavioral Problem-solving 1 0.68 
CBT group 11 0.69 
CBT group+ family 1 1.45 
CBT-individual 1 1.25 
Nondirective support group 1 0.18 
Residential 1 0.40 
Relaxation group 2 1.43 
Role play 1 0.29 
Social skills group 1 0.73 
Note. CBT=Cognitive-Behavioral Therapy. 
Table 13 
Mean Effect Size by Treatment Modality in Pre- and Poststudies 
Treatment N (treatments) Mean ES 
CBT group+ family 1 
CBT-individual 3 
SB family therapy 1 
Individual consultation 1 
Interpersonal therapy-ind 1 
Nondirective individual 3 
Relaxation-individual 1 
Role play 1 
Social skills group 3 
Note. CBT=Cognitive-Behavioral Therapy; Ind=Individual; SB Family 
Therapy=Structured Behavioral Family Therapy. 
1.41 
1.64 
1.61 
0.25 
2.02 
1.05 
0.30 
0.29 
0.88 
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In regards to the types of medications used in the pharmacological trials, the TCA 
imipramine was used most often (n = 4; 29%) and yielded an average effect size of 0.02. 
Other TCAs administered in medication trials included amitriptyline (n = 3; 21 %; Mean 
effect size= 0.40), desipramine (n = 2; 21 %; Mean effect size= 0.39), and nortriptyline 
(n = 2; 21 %; Mean effect size = -0.15). The SSRI fluoxetine was used twice and 
produced an average effect size of 0.30. See Table 14 for a summary of medication type 
and effect size. 
Other Treatment Variables 
Although there is a need to better understand the relationship between the length 
and frequency of treatment and the efficacy of child and adolescent depression 
interventions, exploratory analyses did not yield many compelling trends. For example, 
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Table 14 
Mean Effect Size by Medication in Pharmacological Studies 
Medication N (treatments) Mean ES 
Amitriptyline (Elavil) 3 0.40 
Desipramine (Norpramin) 2 0.39 
Fluoxetine (Prozac) 2 0.30 
Imipramine (Tofranil) 4 0.02 
Nortriptyline (Pamelor) 2 -0.15 
the Pearson product-moment correlation between the standard mean difference effect size 
and the number of therapy sessions was -0.03 (Q = .86). However , there was a modest 
negative relationship between the number of weeks in therapy and the mean effect size 
(r = -0.40; 12. = .07). That is, as the number of treatment weeks increased, the average 
effect size decreased . Moreover , in terms of the pharmacological interventions , the 
problem of truncated range (i.e., 4-8 weeks) precluded a meaningful analysis between the 
duration of treatment and outcome. 
Assessment Measures 
As described previously, the process of assessment has a significant impact on 
treatment outcome studies because the assessment and diagnostic measures that guide the 
inclusion and evaluation of subjects are used to determine the effectiveness of the 
interventions. Of the 23 psychosocial studies , a single self-report measure was used to 
evaluate the treatment in 8 (35%) of them. Further , two other investigations used a 
combination of two self-report measures to assess outcome. The most commonly used 
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the studies, the adult version of the CDI, the BDI, was administered to the adolescent 
subjects. Other commonly used self-report measures included the RCDS, the RADS, the 
MFQ, and the CES-D . 
In terms of combining assessment procedures, 9 of the 23 studies (39%) used both 
self-report measures and diagnostic interview schedules . The modal interview schedule 
used was the K-SADS (n = 7) followed by the CDRS (n = 3) and BID (n = 3). Measures 
of anxiety (e.g., Revised Children's Manifest Anxiety Scale; Reynolds & Richmond, 
1978) were used in three of the studies and the CBCL was used in two trials . There was 
also the sporadic use of other instruments that purport to measure constructs such as self-
esteem, global functioning, and cognitive distortions (Butler et al., 1980). 
Although the interaction between assessment technology and outcome was 
identified as an important issue to examine, it proved difficult to analyze logistically. 
However , in a number of studies, depression outcome measures were used in concert . 
Thus , practical comparisons of two different measures within the same study revealed 
some interesting findings . As shown in Table 15, the assessment strategy often had a 
noteworthy impact on the ES estimates . For example, Kahn et al. (1990) used the RADS 
and the CDI in their study to evaluate the efficacy of cognitive-behavioral group therapy. 
The mean effect size based on the CDI was 1.52, whereas the mean effect size based on 
the RADS was higher at 2.17. In another study, Reynolds et al. (1986) used the BDI and 
the RADS to assess the effectiveness of cognitive-behavioral group therapy. Based on 
the data, the findings were much more convergent, with the mean effect size on the BDI 
at 1.50 and a mean effect size of 1.46 on the RADS. 
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Table 15 
Within-Study Effect Size Comparisons of Assessment Measures 
Study Treatment Measure ES 
Clarke et al. (1995) CBT-G CES-D 0.31 
HRSD 0.28 
Jaycox et al. (1994) CBT-G CDI 0.27 
RCDS 0.35 
Kahn et al. (1990) CBT-G CDI 1.52 
RADS 2.17 
Rlx-G CDI 1.09 
RADS 1.50 
CBT-I CDI 1.04 
RADS 1.47 
Lewinsohn et al. (1990) CBT-G CES-D 1.26 
BDI 0.96 
CBT-G + F CES-D 1.60 
BDI 1.29 
Reynolds et al. ( 1986) Rlx-G BDI 1.58 
RADS 1.56 
Preskom et al. (1987) Imiprarnine CDI 0.21 
CDRS 0.06 
Weisz et al. ( 1997) CBT-G CDI 0.47 
CDRS-R 0.38 
Note. BDI=Beck Depression Inventory ; CBT-G(I)=Cognitive-Behavioral Therapy-Group 
(Individual; F=Farnily); CDI=Children's Depression Inventory; CDRS Children's 
Depression Rating Scale (R=Revised); CES-D=Center for Epidemiological Studies--
Depression Scale; HRSD=Harnilton Rating Scale for Depression; RADS=Reynolds 
Adolescent Depression Scale; RCDS=Reynolds Child Depression Scale; Rix-
G=Relaxation Group. 
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Therapist Variables 
As previously described, therapist variables such as level of training, years of 
experience, and professional discipline are important to consider when evaluating therapy 
outcome. However, due to limited information contained in the articles, only the 
therapist's level of training for psychosocial interventions was coded that included (a) 
paraprofessional therapists (e.g., teachers), (b) graduate trainees, and (c) professional 
therapists. 
Of the 21 controlled psychosocial treatments, graduate students were most often 
in charge of the therapeutic interventions (n = 15; 71 % ) and produced a mean effect size 
of 0.69. Professional therapists led four of the controlled treatments (19%), yielding an 
average effect size of 1.18. There were only two controlled studies in which 
paraprofessional therapists led the treatment , producing a mean effect size of 0.29. 
In terms of the 15 pre-/posttreatments, professional therapists led 11 of them 
(73%) and produced a mean effect size of 1.29. In the remaining four pre-/ 
posttreatments (27%), graduate students and paraprofessional therapists yielded mean 
effect sizes of 0.85 and 0.61, respectively . See Table 16 for a summary of data on 
therapist variables and effect size. 
Severity of Illness and Comorbidity 
As mentioned above, it is important to know whether treatment efficacy is 
affected by the severity of the depressive illness. Thus, three levels of severity were 
coded and analyzed including: (a) "at risk" status (i.e., prevention), (b) presenting 
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Table 16 
Mean Effect Size by Level of Training in Psychosocial Studies 
Type of study Training level N Mean ES 
Controlled psychosocial 
Professional 4 1.18 
Graduate student 15 0.69 
Paraprofessional 2 0.29 
Pre-/postpsychosocial Professional 11 1.29 
Graduate student 2 0.85 
Paraprofessional 2 0.69 
depressive symptomatology, and (c) depressive diagnosis (major depressive disorder). 
While there were different levels of severity in the psychosocial studies, the 
pharmacological studies uniformly assessed the subjects as suffering from major 
depressive disorder. 
Of the 21 controlled psychosocial treatments, three were determined to be 
prevention regimens with a mean effect size of0.17. There were 15 treatments based on 
depressive symptomatology that yielded an average effect size of 0.81, whereas the 
remaining 3 treatments purported to address a diagnosis of major depressive disorder and 
produced a mean effect size of 0.98. 
In terms of the 15 pre-/postpsychosocial interventions, 12 of the treatments 
focused on depressive diagnoses, 2 were designed to address at-risk status, and 1 
intervention targeted depressive symptomatology. The pre-/posttreatments for major 
depressive disorder produced a mean effect size of 1.32, the prevention treatments yielded 
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an average effect size of .49, and the single symptomatology-based intervention yielded 
an average effect size of 0.24. Refer to Table 17 for a summary of data on level of 
severity and effect size . 
Unfortunately, the data regarding comorbidity in the studies were limited and did 
not facilitate many useful analyses. Although descriptive data regarding comorbid 
conditions were provided in a few studies, the data were not suitable for coding to 
investigate potential interactions. Further, in the single psychosocial study that 
specifically addressed comorbid conditions (i.e., Curry & Wells , 1998; depression and 
substance abuse), substance abuse data were not available at the time of this writing. 
However , one finding is important to note. In a pharmacological trial in which the 
efficacy of imipramine was examined (Hughes et al., 1990), the authors reported an 
interaction between major depressive disorder , comorbid conditions , and outcome . 
Patients with major depressive disorder and comorbid anxiety disorders responded much 
better to the medication (Mean effect size = 1.02) than those with major depressive 
disorder and comorbid conduct disorder and/or oppositional defiant disorder (Mean effect 
size= -0.88) . Thus, while there appeared to be null main effects, when the interaction 
between comorbid conditions was taken into account , the data were much more practical 
and useful. 
Quality of Study 
As described above , several researchers have suggested that there is a relationship 
between methodological factors (i.e., study quality) and effect size estimates . The quality 
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Table 17 
Mean Effect Size by Level of Severity in Psychosocial Studies 
Type of study Level of severity N (treatments) Mean ES 
Controlled psychosocial 
Prevention 3 0.17 
Symptomatology 15 0.81 
Diagnosis 3 0.98 
Pre-/postpsychosicial 
Prevention 2 0.49 
Symptomatology 1 0.24 
Diagnosis 12 1.32 
of each study was rated based on: (a) potential threats to internal validity and (b) the 
overall validity of the study. Evaluative guidelines for study quality were based on a 
5·-point Likert scale (1 = unacceptable, 2 = inferior, 3 = fair, 4 = good,; 5 = excellent). 
The standard mean difference effect size estimates were cross-tabulated with the overall 
validity ratings for each study. Based on a linear regression model, the correlation 
between study quality and effect size was 0.67 CJ2 < .0001). That is, as the study quality 
increased, so did the standard mean difference effect size. See Figure 2 for a graphic 
representation of these data. 
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Figure 2. Relationship between study quality and standard mean difference effect sizes. 
CHAPTER V 
DISCUSSION 
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The three research questions that were posed in this investigation addressed : (a) 
the overall efficacy of psychosocial interventions for child and adolescent depression, (b) 
the overall efficacy of pharmacological treatments for child and adolescent depression, 
and ( c) whether there was evidence of differential efficacy for psychosocial and 
pharmacological treatments when a number of variables were considered . This chapter 
includes a detailed interpretation of the results followed by a review of the clinical 
implications of the findings. The limitations of this investigation are discussed and 
suggestions for future research are presented. 
Main Effects 
Psychosocial Studies 
The results of this comprehensive review indicate that overall, psychosocial 
treatments for early-onset depression lead to a substantial reduction in depressive 
sequelae in children and adolescents regardless of whether the experimental design was a 
between- or within-group study. The overall mean difference effect size for controlled 
studies was 0.74 at posttreatment, indicating that the average child who received 
treatment for depression was better off than approximately 77% of the children who did 
not. Furthermore, the treatment effects were durable over a brief period of time 
(median= 6.5 weeks), as the mean effect size was 0.64 for the controlled studies that 
reported follow-up data. 
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A practical interpretation of the overall effect sizes for controlled studies suggests 
that the effects were robust and clinically meaningful. That is, a mean change of 0.74 
standard deviation units across a variety of instruments that purport to measure depressive 
sequelae would move a number of youth in the treated group from a clinical range to a 
nonclinical range. For example, Stark et al. (1987) reported that the mean CDI score of 
the treated group was 8.04 at posttreatment , as compared to 18.60 for the control group . 
Thus , with a standard deviation of approximately 10 on the CDI, an effect size of0 .74 
would account for almost an 8-point difference on the CDI scores at posttreatment. This 
difference , in turn, moved a large group of treated subjects into the nonclinical range (i.e., 
< 11) based on the suggested interpretation of CDI scores by the instrument's author 
(Kovacs , 1992). 
These findings mirror global reviews of psychotherapy with children whereby the 
treated youngsters fared much better than wait-list or no-treatment control subjects at 
posttreatment and follow-up (effect size= 0.71; Casey & Berman , 1985; effect size= 
0.88; Kazdin et al. , 1990; effect size= 0.79 ; Weisz et al., 1987; effect size= 0.71 ; Weisz , 
Weiss, et al., 1995). These data are also convergent with the findings from more 
circumscribed meta-analytic reviews that support the efficacy of social skills 
interventions for depressed youth (effect size= 0.76; Black-Cecchini, 1996), cognitive-
behavioral therapy for adolescents ( effect size = 1.02; Reinecke et al., 1998), and a 
smaller sample of depression treatments (effect size= 0.67; Weisz, Weiss et al., 1995). 
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Furthermore, these findings are consistent with the data from a large number of studies 
that support the efficacy of psychosocial treatments for depressed adults. 
In regards to the pre-/postpsychosocial studies, the overall mean effect size at 
posttreatment was 1.14, which indicates that the treated subjects experienced significant 
reductions in depression at posttreatment. These findings were also durable over time 
(median= 36 weeks), with a mean effect size of 1.26 for the studies in which follow-up 
data were reported . However, as mentioned previously, these effect sizes were 
calculated based on intrasubject variance and comparisons between the overall effect size 
of the controlled and pre-/poststudies were inappropriate. Therefore, in order to facilitate 
a useful comparison of the mean effect size of the between- and within-subject group 
designs, pre-/post effect sizes were also calculated for the controlled studies. The overall 
mean ES for controlled studies using intrasubject variance estimates was 1.23, which is 
comparable to the mean effect size for pre-/poststudies (1.14). 
Given these roughly commensurate values, a case could be made that the 
treatments in pre-/poststudies led to equally substantial reductions in depressive sequelae 
despite the methodological limitation of not having wait-list or no-treatment control 
group comparisons. Further, if the data regarding the average reduction of depression in 
control-group subjects (0.37) is subtracted from the pre-/post-effect size estimates of 
treated subjects in between-group studies (1.23), the resulting value (0.86) approximates 
the overall mean effect size for controlled studies (0.74). Therefore, although the overall 
effect size for pre-/poststudies was relatively inflated because there were no wait-list or 
control group comparisons, the similar pre-/postvalues across methodological designs 
augment the overall findings that psychosocial interventions are efficacious in the 
treatment of early-onset depression. 
Pharmacological Studies 
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The results of this meta-analytic review indicate that in general, pharmacological 
treatments for early-onset depression do not lead to a substantial reduction in depressive 
sequelae in children and adolescents. The overall mean effect size at posttreatment was 
0.19, suggesting that the average subject who was administered the active medication 
moved to the 58th percentile in the distribution of subjects who took a pharmacologically 
inert placebo. It is unclear whether these effects were maintained over time as follow-up 
data were not reported in the pharmacological studies. Further, the average placebo 
response rate across all of the studies was high (43%; range 17% - 68%), indicating that 
much of the derived benefits from pharmacotherapy were produced by the children's 
expectations of the treatment as opposed to the active medication itself. 
In comparison to the only other meta-analytic review located on the efficacy 
pharmacotherapy for depressed youth (ES= 0.35; Hazell et al., 1995), these findings were 
somewhat more discouraging but roughly consistent, suggesting that antidepressant 
medications are not substantially superior to placebo in treating depressed youth. At the 
same time, these data are inconsistent with the empirical evidence that the use of 
psychotropic medications in adults suffering from depression is efficacious, with an 
average positive response rate between 65% and 75% (Elkin, 1994; Speier et al., 1995; 
Thase & Kupfer, 1996). 
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However, a number of important points must be made about the interpretation of 
these main effects . First, as Conners (1992) aptly pointed out, "various methodological 
problems limit the conclusions" of pharmacological studies since there are substantial 
differences in the criteria for improvement , instrumentation , and selection procedures. 
Thus, in the present investigation, the pharmacological findings represent a synthesis of 
data that are, in many ways, flawed (i.e., difficulty transforming response rates to effect 
sizes) . For example, in one study improvement might be defined as evidencing a 50% 
reduction in depressive symptoms as measured by the CDI, whereas one of the criteria for 
improvement in another study might be a score of 26 or less on the CDRS. The resulting 
dichotomous determinations of "improved" versus "not improved" in the active and 
placebo conditions are markedly different across the two studies, which , in turn , renders 
the calculation and comparison of effect sizes across the divergent improvement criteria 
problematic. Nonetheless , these data certainly reveal some important trends about the 
efficacy of pharmacological treatments for depressed youngsters and the findings are 
congruent with most , if not all, of the qualitative interpretations presented within each of 
the studies . 
Second , as a number ofresearchers have suggested (Anderson , 1995; Birmaher et 
al., 1996a; Kye & Ryan, 1995), firm conclusions about the efficacy of antidepressants in 
young people cannot be made until a larger body of literature is accumulated whereby 
some of the methodological limitations are addressed in future studies. Furthermore, of 
the 14 pharmacological studies included in the present analysis , only two controlled trials 
(14%) were located that utilized an SSRI (Emslie et al., 1997; Simeon et al., 1990). The 
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vast majority of the trials (n = 11) used TCAs (79%). Thus, the negative main effects of 
antidepressant medications for early-onset depression are attributable primarily to a lack 
of TCA efficacy, not necessarily pharmacotherapy overall. 
Third, the number of weeks of pharmacotherapy across studies ranged from 4 to 8 
weeks (median= 6). Thus, given the fact that it often takes a month or more to evidence 
benefits from TCAs (Duman et al., 1997), it is possible that posttreatment evaluations 
were premature and not enough time had passed to accurately assess the effects of the 
medications. 
Given the limited evidence of TCA efficacy in children and the curiously high 
placebo-response rates in younger groups, several researchers have attempted to explain 
these findings based on the principles of pharmacokinetics. According to Stedman's 
Medical.l)ictionarv (1995), pharmacokinetics is defined as "the process by which a drug 
is absorbed, distributed, metabolized and eliminated by the body" (p. 630). For example, 
Geller et al. suggested that more frequent dosing is required for children and adolescents 
in light of the fact that they metabolize and excrete many of the antidepressant 
compounds more rapidly than adults (Geller et al., 1986). Similarly, several authors have 
reported statistically significant correlations between higher plasma levels of TCAs and 
clinical improvement in children with major depression ( e.g., Preskom et al., 1982; Puig-
Antich et al., 1987). However, this finding is equivocal and in need of replication 
(Birmaher et al., 1996a). For instance, Clein and Riddle (1995) reported that 
the lack of demonstrated efficacy of TCAs in double-blind, placebo-
controlled studies in the treatment of childhood depression does not appear 
to be a pharmacokinetic phenomenon because frequent dosing has 
adequately addressed this issue. (p. 68) 
Other pharmacokinetic hypotheses have been proposed to explain the lack of 
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antidepressant efficacy in children and adolescents. Murrin, Gibbens, and Ferrer (1985) 
suggested that because most of the antidepressant medications (i.e., tertiary amines , 
noradrenergic TCAs) that were used in the trials purportedly enhance noradrenergic 
functioning , the fact that the noradrenergic systems are not fully developed until 
adulthood might dampen or limit the effectiveness of such medications in children . In 
contrast , there is evidence that the serotonergic and cholinergic systems develop earlier 
(Clein & Riddle, 1995), which might set the stage for additional controlled studies of the 
SSRis in children and adolescents in the future. It has also been suggested that the lack of 
positive response to antidepressant medications in adolescents might be due to hormonal 
factors that interfere with certain TCAs during puberty (Birmaher et al., 1996a). 
In terms of the high placebo response rates in child and adolescent samples , a 
number of hypotheses have been advanced. For example , Morris and Beck (1974) 
suggested that children have generally higher placebo response rates than adults. In 
addition , Birmaher et al. noted a number of potential factors associated with the high 
placebo response rates including: (a) the instability of affective states in juvenile groups ; 
(b) the inclusion of children who evidence only mild to moderate depressive 
symptomatology; and (c) the prevalence of comorbid syndromes, especially disruptive 
behavioral disorders (Birmaher et al., 1996a). 
A third and final comment about the interpretation of the main effects of 
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pharmacological trials is based on the interaction between study variables ( e.g., length of 
treatment, age , treatment setting, medication type) and outcome . Indeed, a number of 
interesting trends were revealed about the efficacy of pharmacological interventions when 
several variables were taken into account. These data are summarized in the following 
section on Study Variables. 
Summary 
In summary, it appears that psychosocial interventions lead to substantial 
reductions of depression in youngsters, whereas pharmacological interventions are not 
superior to pill placebo in ameliorating depressive sequelae in children . There was only 
one study (Mandoki et al., 1997) in which pharmacotherapy was compared with an active 
psychosocial treatment and both interventions led to substantial reductions in depression 
as determined by the outcome measures . Nonetheless, because the evidence is somewhat 
indirect, it appears that psychosocial interventions are superior to pharmacotherapy in 
treating depression in youth given the current findings reported in the literature . At the 
same time, the methodological limitations of the pharmacological studies are noteworthy 
and may be masking otherwise efficacious findings. Further, in light of the interactions 
between study variables and outcomes that are discussed in the following section , 
comparisons between psychosocial and pharmacological interventions are placed within a 
more appropriate context. 
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Study Variables 
As described previously, a false dichotomy was created whereby child studies 
were defined as having a mean age of 12 or younger and adolescent studies were 
characterized by a sample with a mean age of 13 or older. In the psychosocial studies, the 
mean effect size for adolescent samples were higher than the mean effect size for child 
samples, regardless of experimental design. These findings were consistent with a prior 
study in which the mean effect size was higher for adolescents than for younger children 
(Weisz, Weiss, et al., 1995). However, these data were divergent from an earlier study in 
which psychotherapy was more efficacious for children than for adolescents (Weisz et al., 
1987). 
Similarly, the interaction between age and pharmacotherapy indicated that 
medication was more effective for adolescents than for children. Indeed, the mean ES 
was almost twice as large for adolescents (0.28) as it was for children (0.15) . Thus, 
overall , it appears that psychosocial and pharmacological interventions for depressed 
youth are more effective for adolescents than for children. Although the reasons for 
these moderate findings of differential effectiveness based on age are difficult to 
determine, some possible hypotheses are offered. Based on the descriptive data, the 
modal psychosocial treatment was cognitive-behavioral therapy in group, individual, or 
family formats. Further, given the fact that a number of CBT interventions might depend 
upon a certain level of cognitive development, younger children might not be as 
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responsive to more cognitively sophisticated therapies. Thus, the overall findings, which 
consist of a predominance of CBT interventions , might favor older subjects with the 
assumption that they have better developed cognitive skills and derive increased benefits 
from the cognitively oriented interventions. With regard to the modest differential effects 
based on age in pharmacological studies, these findings might be attributable, in part, to 
the predominance of TCA trials and the empirical data that indicate younger children may 
not respond favorably to TCAs since their noradrenergic systems are not fully developed 
until late adolescence and early adulthood (Murrin et al., 1985). 
Psychosocial interventions for depression were somewhat more efficacious when 
the average percentage of female subjects was 60% or greater. These findings are 
consistent with the data from other reviews that lend support to the trend of differential 
efficacy in favor of female subjects (Casey & Berman, 1985; Weisz, Weiss, et al. , 1995). 
However, these findings were far from compelling and more information is needed to 
better understand the relationship between sex and the treatment of early-onset 
depression , especially given the epidemiological data, which indicate that the female-to-
male ratios for depressive illness begin to approximate the base rates for adult depressive 
disorders (i.e. , approximately 2:1) during middle to late adolescence. A possible 
explanation for the differential outcomes in favor of female subjects might be related to 
societal expectations regarding gender-appropriate behavior. That is, given the fact that 
females are, in general, socialized and expected to be more emotionally expressive than 
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their male counterparts, most forms of psychotherapy in Western culture are congruent 
with these socialization forces in that they promote and reinforce increased levels 
emotional expression. As such, female subjects potentially have an advantage over the 
male subjects because many of our therapeutic regimens are consistent with what they 
have been socialized to do from a very early age. 
Referral Source 
The data on the interaction between referral source and treatment outcome 
revealed some interesting trends. In controlled studies, 18 of the 21 (86%) interventions 
included nonreferred subjects and yielded an ES of 0.79. Because this ES estimate 
encompassed the vast majority of controlled treatments , it closely approximates the 
overall ES for controlled studies (0.74). Although three of the controlled studies included 
referred subjects and produced a smaller ES (0.44), this finding was not robust and 
included two outlier ES estimates near zero. Similarly, the majority of pre-/ 
posttreatments (80%) included clinically referred subjects and produced a mean effect 
size of 1.20, which is commensurate with the overall ES for within-group designs (1.14). 
Further, although the mean effect size for nonreferred subjects was somewhat smaller 
than the mean effect size for referred subjects, the finding was based on only three studies 
so it must considered tentative . In light of these data, it appears that psychosocial 
interventions led to substantial reductions in depressive sequelae regardless of whether 
the sample was clinically referred or not. In sum, these findings suggest that analog 
studies can be used to provide useful data in the treatment of clinically depressed youth. 
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Treatment Setting 
The school(!!= 15) was the modal setting (75%) for controlled psychosocial 
treatments and yielded an average ES (0.75), which was equivalent with the overall effect 
size for between-group designs (0.74). Similarly, the vast majority of pre-/posttreatments 
took place in outpatient clinics(!!= 12; 80%) and produced a mean effect soze (1.22) that 
was roughly commensurate with the overall pre-/post-effect size (1.14). Although there 
were only two inpatient psychosocial treatments , they were substantially less effective 
(0.29) than interventions conducted in schools or outpatient clinics. A similar pattern of 
differential efficacy was apparent in the pharmacological trials as well. Medication trials 
conducted in inpatient settings(!!= 6) were essentially ineffective (effect size= -0.06) 
when compared to outpatient pharmacotherapy (!! = 8; effect size= 0.26). 
Overall , when the treatment setting and the referral source are taken into account, 
controlled psychosocial interventions involved mostly nonreferred subjects in school 
settings and produced moderately large treatment effects, whereas pre-/posttreatments 
included a predominance of clinically referred youngsters in outpatient settings and also 
led to substantial reductions in depressive sequelae. Further , it appears that inpatient 
treatments for depression are substantially less effective than interventions conducted in 
other settings , regardless of whether they are psychosocial or pharmacological in nature . 
This finding might be associated with the notion that inpatient subjects are not only 
clinically referred, but perhaps more seriously depressed than their peers who are 
receiving treatment in schools or outpatient clinics (Wiesz, Donenberg, et al., 1995). In 
addition , subjects from inpatient settings often present with a broader range of risk factors 
than outpatient groups (e.g., multiple diagnoses , legal and family problems). Thus, 
treatments focused on a specific problem (i.e., depression) may not be adequate for 
children who present with more complicated sequelae. 
Type of Treatment 
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Cognitive-behavioral therapy (CBT) was, by far, the most common type of 
psychosocial treatment for depressed youth regardless of experimental design or format 
(individual, group, family) . Of the 36 treatments reviewed, 17 (47%) were based on 
cognitive-behavioral principles and 11 (31 %) were cognitive-behavioral group 
interventions. Despite the fact that the CBT group was the modal controlled treatment, it 
was not the most effective despite a moderately large and robust effect size of 0.69. 
Lewinsohn et al. (1990) combined CBT group with family therapy which produced a 
mean effect size of 1.45. In addition, two group relaxation regimens (Kahn et al., 1990; 
Reynolds & Coats, 1986) were found to be efficacious in reducing depressive symptoms 
in children when compared to no-treatment control group subjects (effect size= 1.43). 
Other controlled interventions that yielded equivalent or more substantial effect sizes than 
CBT group included social skills group therapy (n = 1; effect size= 0.73) and behavioral 
problem-solving (n = 1; effect size= 0.68). Thus, although CBT interventions are 
frequently implemented and widely regarded as significantly superior to other 
interventions ( e.g., Jayson, Wood, Kroll, Fraser, & Harrington, 1998), this assertion 
might be an overstatement and it is not necessarily supported by the existing empirical 
data. At the same time, there were a limited number of non-CBT studies, so the stability 
of these findings remains in question. 
In terms of the 15 treatments examined in pre-/poststudies, although CBT 
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interventions were common(!!= 4; 27%), there was balance and diversity among the 
remaining treatments including three social skills groups (20%), three nondirective 
individual interventions (20%), interpersonal therapy (n = 1; 7%), individual relaxation 
(n = 1; 7%), structured behavior family therapy (n = 1; 7%), and role play therapy (D = 1; 
7%). Similar to the findings from controlled treatments, CBT interventions, while 
efficacious, were not vastly superior to a number of other types of psychosocial 
interventions. Indeed , interpersonal therapy, structured behavioral family therapy , and 
nondirective interventions all produced large and roughly commensurate treatment 
effects. 
Another noteworthy finding regarding treatment type and effect size was the 
apparent detrimental impact of attention-placebo conditions. Two studies (Butler et al., 
1980; Liddle & Spence, 1990) included attention-placebo groups that produced a 
detrimental effect (-0.83) when compared to no-treatment controls. This was a curious 
finding given the intended purpose of an attention-placebo condition, which purportedly 
controls for improvement related to variables such as equal time and attention . However, 
in the case of these two attention-placebo conditions, simply measuring levels of 
depression (i.e., no-treatment controls) was more efficacious than providing a sample of 
children with nonspecific time and attention . 
In regards to the efficacy of particular types of medications used in the 
pharmacological trials, amitriptyline (Elavil) produced the highest ES (0.40; n = 3), 
followed by desipramine (Norpramin; 0.39; n = 2) and fluoxetine (Prozac; 0.30; n = 2). 
The least effective medications were imipramine (Tofranil; 0.02; n = 4) and nortriptyline 
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(Pamelor; -0.15; n = 2). As mentioned previously, the predominant type of medication 
used in child pharmacological trials was TCAs, which have not been shown to be 
effective in younger groups. On the other hand, the most recent and large controlled 
medication trial (Emslie et al., 1997) utilized an SSRI (i.e., Prozac) that proved to be 
substantially superior to pill placebo in ameliorating early-onset depression (Mean effect 
size= 0.59). As such, this relatively efficacious finding is concealed by the overall effect 
size for pharmacological studies. 
In sum, the interaction between treatment type and ES reveals some important 
findings. For instance, it appears that although CBT produces large and robust treatment 
effects, other interventions lead to equally substantial improvements in depression . This 
is not necessarily an endorsement of the dodo verdict in terms of early-onset depression 
treatment outcomes, but the data do not support the assertion that one type of treatment, 
namely cognitive-behavioral therapy, is significantly superior to other types of 
interventions. In regards to pharmacological medications, Elavil, Norpramin, and Prozac 
appear to be moderately superior to placebo in treating child and adolescent depression 
and there is developing evidence that SSRis might be the medication of choice in future 
clinical trials. 
Further, given the evidence that SSRis are potentially less dangerous and produce 
fewer side effects than TCAs, these data provide some compelling and encouraging 
reasons to substantially increase our empirical understanding of the efficacy of such 
medications for the treatment of depressed youth. 
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Other Treatment Variables 
The data regarding the interaction of frequency (i.e. , number of sessions) and 
treatment outcome for depressed youth revealed some interesting trends. For example, 
as mentioned above, the length of the pharmacological trials and the TCA studies in 
particular was perhaps too brief (i.e., 4-8 weeks) to detect treatment effects , given that it 
often takes up to a month to evidence benefits. In addition, there was a modest negative 
relationship between the length of therapy (i.e., number of weeks) and the mean effect 
size (r = -0.40 ; .Q = .07). That is, as the number of treatment weeks increased, the average 
effect size decreased. As such, these data might indicate that the treatment effects level 
off or diminish over time, but these findings should be interpreted with caution given the 
fact that they were not statistically significant nor practically compelling. Further, this is 
an important empirical question given the evidence from the adult literature , which 
indicates that most of the benefits of psychotherapy are obtained during the first 8-10 
sessions . However, this does not necessarily imply that important gains are not made 
after the first 10 sessions. Indeed , in a number of health-related treatments ( e.g. , 
chemotherapy for cancer) , the patient gets substantially worse before getting better. Thus, 
for individuals who suffer from some forms of depression , it is possible that the course of 
the disease worsens before improving, and discontinuing treatment prematurely based on 
inadequate data would be a disservice to clients. In sum, more information is needed to 
better understand the relationship between these variables and treatment efficacy for child 
and adolescent depression, especially given the current economic climate in which brief, 
empirically supported treatments are the battle cry of many, if not all, insurance 
companies and managed-care organizations. 
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Assessment Measures 
As described previously, measuring treatment efficacy depends exclusively on 
assessment technology. While there were a number of studies that employed multiple 
depression measures to determine outcome (e.g., Brent et al., 1997; Emslie et al., 1997; 
Kahn et al., 1990), there was a general overreliance on self-report measures across 
psychosocial and pharmacological studies. Thus, given the evidence that depression, as 
measured by self-report devices, attenuates over time and repeated administrations, it is 
likely that some of the improvement depression treatment studies was attributable to 
extraneous variables such as the mere passage of time and regression towards the mean 
(Hsu, 1995). These data highlight the importance of no-treatment control groups and a 
broad array of assessment devices in clinical trials. 
In addition, every intervention study involves demand characteristics. For 
example, when children present for treatment, they are aware that others expect them to 
improve and might therefore self-report fewer symptoms in an effort to confirm that 
expectation (Orne, 1969; Rosenthal, 1995). It is plausible that older relative to younger 
participants and female compared to male respondents are more sensitive to the demand 
characteristics of the treatment and testing situations. Thus, the larger effect size 
estimates for older subjects and female majority samples may reflect expectancy effects 
rather than genuine effects of treatment. 
Furthermore, practical comparisons of two different measures within the same 
study indicated that some instruments revealed moderately divergent effect sizes. For 
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instance , the effect size difference between two self-report measures of depression in one 
study (Kahn et al., 1990) was substantial (0.65). In other examples, there were discrepant 
findings within the same study depending on the source of the outcome data. Using the 
percent improved data, the ES in the study by Geller et al. (1990) was -0.61 as compared 
to the SMDES on the CDRS (0.49). Moreover, in the study by Geller et al. (1992), the 
effect size based on the percent improved was 0.46 as compared to a less impressive effect 
size on the CDRS of 0.12. Thus, these data illustrate rather clearly that it can be 
dangerous to make firm decisions about treatment efficacy given the limitations of 
assessment procedures. On the other hand, effect size estimates based on two different 
measures were remarkably convergent in another study (e.g., 0.04 difference between BDI 
and RADS ; Reynolds & Coats, 1986). Overall, it appears that the best way to prevent a 
great deal of measurement error in child depression outcome studies is to administer a 
broad array of devices that purport to measure depression and related constructs. 
Therapist Variables 
Professional therapists consistently produced a higher mean effect size in treating 
depressed youth than either graduate trainees or paraprofessional therapists , regardless of 
the experimental design. Graduate trainees, in turn, were more effective than their 
paraprofessional counterparts who produced the smallest effect sizes overall. These data 
are congruent with the findings from large meta-analytic reviews which indicate that 
professional therapists are more effective than their less trained counterparts (Stein & 
Lambert, 1995; Weisz et al., 1987). 
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Similar to the data regarding referral source and treatment setting, the majority of 
controlled treatments (with nonreferred subjects in schools) were most often led by 
graduate trainees. In contrast, pre-/posttreatments (with referred subjects in outpatient 
clinics) were led predominantly by professional therapists. Nonetheless, these findings 
lend support to the idea that increased levels of training and experience in psychotherapy 
lead to enhanced treatment outcomes, much to the delight of graduate training directors 
everywhere. 
Severity of Illness and Comorbidity 
Overall, it appears that psychosocial interventions for depressed youth were 
effective regardless of whether the children were treated based on depressive 
symptomatology or a diagnosis of major depressive disorder and/or dysthyrnia. In 
contrast, the mean effect sizes of prevention studies were substantially lower across 
controlled and pre-/posttreatment designs . This finding was expected, based on the 
intuitive assumption that the children in at-risk studies were less depressed that the 
subjects in symptom- or diagnosis-based trials . Further, in prevention studies, the failure 
to detect elevated levels of depression is not only expected , but it is an artifact of 
measurement limitations (i.e., floor effect, limited sensitivity to low levels of depression) . 
The lack of treatment effect in prevention studies does not diminish their importance . 
Indeed , it is difficult to assess when something did not happen! At the same time, it 
illustrates the need to follow at-risk samples longitudinally in comparison to no-treatment 
controls . 
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Unfortunately, as mentioned previously, the data regarding comorbidity were 
limited. This was especially disappointing given the evidence that comorbid conditions 
involving depression lead to poorer outcomes, prolonged morbidity, and increased 
vulnerability to future bouts of depression ( e.g., Kovacs , 1998; Newman et al., 1996). 
However, there was one provocative finding regarding the interaction of comorbidity and 
depression treatment outcome. In a pharmacological trial in which the efficacy of 
imipramine was examined, Hughes, Preskom, Wrona, et al. (1990) reported that patients 
with major depressive disorder and comorbid anxiety disorders responded much better to 
the medication (mean effect size= 1.02) than those with major depressive disorder and 
comorbid conduct disorder and/or oppositional defiant disorder (mean effect size= 
-0.88. Thus, while there appeared to be null main effects, the data clearly revealed 
evidence of differential efficacy when comorbid diagnoses were taken into account. 
Further research is needed to better understand the relationship between comorbid 
diagnoses and the treatment of child and adolescent depression. 
Quality of Study 
There is a moderately strong and statistically significant relationship between the 
quality of study and the mean effect sizes for early-onset depression outcome studies. This 
finding was contrary to the hypothesis proposed by Wilson and Rachman (1983), wherein 
it was suggested that methodologically weaker studies might skew the results from meta-
analytic reviews in the direction of an overestimation of treatment effects. However, the 
data from the present study were congruent with the findings reported by Weiss and Wiesz 
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Weiss and Wiesz (1990) whereby increased levels of methodological rigor were 
associated with higher mean effect size estimates . Further, Weiss and Wiesz suggested 
that experimental factors accounted for almost as much variance as the more substantive 
elements such as treatment type and age. Therefore, these data provide compelling 
evidence that methodological factors should be carefully considered during the 
development and implementation of experimental treatments for child and adolescent 
depression . At the same time, it appears less likely that studies with more limited 
controls will dangerously skew the findings. 
Summary and Clinical Implications 
The overall findings of this meta-analysis indicate that several different 
psycho social interventions for early-onset depression produce moderate to large treatment 
gains that are clinically meaningful for many afflicted youth . Further , it appears that 
psychosocial treatments are, in general , superior to pharmacological regimens in treating 
depressed children and adolescents. However , there is also recent evidence that SSRls 
such as fluoxetine are efficacious, and they will likely play an increased role in the 
management of affective illness in youngsters . 
In terms of the clinical implications of these findings , it appears that two related 
but unique bodies of literature within the domain of child depression treatment studies 
have developed. On the one hand, there are a number of controlled studies with 
nonreferred children suffering from depressive symptoms who derive substantial benefit 
from school-based interventions led mostly by graduate students . On the other hand, 
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there are a large number of pre-/poststudies with referred children suffering from 
depressive diagnoses who benefit greatly from outpatient treatments led predominantly by 
professional therapists. Taken together, the implications are promising and likely 
generalizable to everyday clinical practice since the findings are not simply based on 
analogue samples or mildly depressed youngsters. Further, it appears that clinicians can 
select from and even combine various treatment technologies that produce roughly 
commensurate effects in ameliorating depressive sequelae in their clients. Finally, given 
the data regarding the relative superiority of psychosocial interventions over medication 
for depressed youth, clinicians should consider psychosocial treatments to be first-line 
interventions until there are more definitive answers regarding the efficacy and safety of 
pharmacotherapy for child and adolescent depression. This may contradict the oft-held 
assumption that medication is the treatment of choice when compared to psychosocial 
alternatives to treating psychopathological disorders. However, based on the findings 
from this review, this assumption should be challenged and the present data should be 
integrated into clinical practice, regardless of whether one is a pediatrician, psychologist, 
psychopharmacologist, or psychiatrist. Furthermore, while it is true that recent results 
from pharmacological trials have showed increased efficacy ( e.g., Emslie et al., 1997), 
one should remain mindful of the fact that psychosocial interventions produce moderate 
to large treatment effects without the possibility of noxious side effects or an adverse 
impact on child development. 
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Limitations and Future Research 
Perhaps the most compelling limitation of the present investigation is the fact that 
the vast majority of the 37 psychosocial and pharmacological studies (29; 78%) were 
published after 1990. Thus, this is a relatively new and quickly expanding body of 
literature. As such, it was a challenge to keep up with all of the new developments 
regarding the treatment of early-onset depression and it is likely that some important 
findings were not included in the present analysis (i.e., file drawer problem, unpublished 
manuscripts, etc.). Another limitation is based on the calculation of ES for 
pharmacological trials. As mentioned previously, the pharmacological findings represent 
a synthesis of potentially flawed data wherein effect sizes were calculated based on a 
transformation of divergent dichotomous variables (i.e., improvement in the active and 
placebo conditions). 
Given the overall findings and these limitations, there are several important 
recommendations regarding future empirical efforts to investigate the efficacy of 
treatments for early-onset depression . First, future researchers should explicitly report 
findings based on age, sex, and comorbid conditions, in light of the limited interactional 
data that could be obtained regarding these important variables. Second, more consistent 
improvement criteria should be developed for pharmacological trials to facilitate more 
useful comparisons across studies. Third, researchers should attend closely to 
methodological variables when developing future outcome trials given the positive 
correlation between experimental rigor and effect size. Finally, similar to adult studies, 
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large controlled clinical trials examining the efficacy of psychosocial and 
pharmacological interventions for child and adolescent depression should be developed 
and implemented to provide additional insights into this vital health-care issue. 
In terms of how these findings might inform policy, a few recommendations are 
offered. First, given the evidence that child and adolescent depression is prevalent and 
leads to a number of negative outcomes, diligent efforts are needed to fund and develop 
effective treatments for these disabling conditions. Second, more information regarding 
the prevention, identification, and treatment of early-onset depression should be 
disseminated to a broad range of health-care providers (e.g., pediatricians), child service 
professionals (e.g., day-care providers), and child-focused settings (e.g., schools). 
Finally, the treatment of early-onset depression should be considered a vital health-care 
issue worthy of considerable time and expense in hopes of easing the suffering of a 
substantial number of young people. 
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APPENDIX 
APPENDIX 
Coding Form 
Column(s) ES! ES2 ES3 ES4 ES5 ES6 Variable 
1,2 Study ID # 
3,4 ES # 
5,6 Year of Publication 
7-10 Mean age at beginning 
11-13 % female 
14-16 Total n Experim ental 
17-19 Total n Control 
20 Referral: I= clinical 
2=nonclinical 
2 1 Setting: I =school ; 2=outpt ; 
3=inpt 
22 Therapist: 1 =paraprofes sional ; 
2=graduate ; 3=professional 
23 Design : I =pre/post ; 
2=exp (i.e., control group) 
24 Com orb id Dx: I =yes; 2=no 
Type: 
25 Level of intervention : 
1 =prevention 
2=symptomatolog y 
3=diagnosis 
26,27 Total # of sessions 
28-30 Total # of weeks 
31-33 Total # of hours 
34 Type of intervention: 
1 =ind; 2=group ; 3=famil y 
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35,36 Treatment modality : 
I =CBT; 2=RP; 3=Relax ; 4=SS; 
5=Psyed ; 6=NDST ; 7=IPT; 8=fam; 
9=UC; IO=Con ; J J=plac ; 
J 2=medication 
37 Self-Report Measure : 
I =CDI; 2=BDI; 3=RCDS ; 
4=HRSD ; 5=CESD ; 6=RADS ; 
7=MFQC ; other (specify) 
38 Dx Interview : I =yes ; 2=no 
Type : 
Other measures : I =yes; 2=no 
Type: 
SMDES Comparison 
write in ... 
39-43 SMDES ±. _. __ 
44 Follow-up : I =yes; 2=no 
45-47 Length of Follow-up (wks) 
48- 52 Follow-up SMDES 
53 Quality of Study : Validity : 
1 =unacceptable 
2=poor 
3=fair 
4=good 
5=excellent 
Threats to Validity (0-3) : 
maturation : 
history: 
testing : 
instrumentation: 
regression : 
selection bias : 
experimental mortality : 
O=not a plausible threat 
I =minor threat 
2=plausible threat 
3=by itself could explain findings 
Note : Aer Exer=Aerobic Exercise; Alt-Tx=Alternative Treatment; Attn-Plac=Attention-Placebo 
Group ; CBT-G=Cognitive-Behavioral Therapy-Group; CBT-I=Cognitive-Behavioral Therapy-
Individual; Consult=Consultation; F=Family Therapy ; IPT-I=Interpersonal Psychotherapy-
Individual; NFI-I =Non-focused Intervention-Individual ; NST-I=Non-Directive Supportive 
Therapy-Individual; P=Parent; PS-G=Problem-Solving Group ; PsyEd-G=Psychoeducational 
Group ; Rlx-I=Individual Relaxation Therapy ; Rlx-G=Group Relaxation Therapy; RP-G=Role-
Play Group; SS-G=Social Skills Group ; SBFT=Structured Behavior Family Therapy. 
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